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Abstract 
Hericium erinaceus’ also known as monkey head mushroom, is one of the 
common edible mushrooms consumed in China and Japan. The antidiabetic 
potency of the polysaccharides isolated from H. erinaceus has been reported 
previously with promising results. However studies of the detailed extraction 
methods and the mechanisms of the hypoglycemic action are not available. Thus 
the objective of this research is to evaluate the antidiabetic activity of structurally 
characterized polysaccharides extracted from the fruiting body of H. erinaceus 
(HE). 
A small-scale hot water extraction of polysaccharide from HE gave a yield of 
51.52%. The hot water crude extract was purified by dialysis, and 
deproteinization by the Sevag method to produce a deproteinized polysaccharide 
fraction, HE-DP. A scale-up hot water extraction of desugared HE powder, based 
on the conditions of the small-scale one was followed. This crude extract was 
further fractionated according to its water solubility at 4°C. The cold-water 
soluble portion, designated as HE-CS, was collected as supernatant after 
centrifugation and lyophilization. The cold-water insoluble fraction was then 
redissolved in hot water to give a new fraction，termed as HE-CI. These 2 
fractions, HE-CS and HE-CI, had a yield of 2.34 % and 1.87 %, respectively on 
dry weight basis of the HE desugared powder in the large scale extraction. 
Structural analysis of the HE-polysaccharides revealed that (l-^6)-linked glucan 
was the major component in HE-CS while (1^3)-linked glucan was dominant in 
HE-CI. 
The in vitro inhibition of the glucose diffusion by the HE-CS and HE-CI was 
determined by the glucose diffusion retardation index (GDRI). The viscous 
HE-CI inhibited significantly the glucose diffusion 20 minutes after the start of 
the experiment and lasted until the end, with the highest GDRI value of 45.02 
being found at 90 minutes. HE-CI could also significantly decrease the in vitro 
enzymatic activity of a-amylase by 86% at 20 minutes' time. Significant 
inhibitions of a-amylase activity by HE-CI were also found at 120，150 and 180 
minutes. In contrast, HE-CS did not significantly impede the glucose diffusion 
and activity of a-amylase. 
In the oral glucose tolerance tests on normal mice, the hyperglycemia induced by 
iii 
glucose was not ameliorated by oral feeding of HE-CS and HE-CI. The reasons 
for the ineffectiveness of HE-CS and HE-CI in lowering the postprandial high 
blood glucose level might be the acidification, neutralization and dilution effects 
on the change of the physico-chemical properties of HE-polysaccharides during 
the transit in the gastrointestinal tract of mice. 
In the in vivo hypoglycemic test of normal mice, intraperitoneal injection {Lp.) of 
HE-CS and HE-CI could significantly lower the blood glucose level. The highest 
hypoglycemic effects of HE-CS and HE-CI at a dosage of 100 mg/kg of mice 
body weight were 56% at 6 hours and 41% at 24 hours, respectively. In the 
streptozotocin-induced diabetic mouse model, i.p. injection of HE-CS (200 
mg/kg) and HE-CI (100 mg/kg) significantly reduced the blood glucose level to 
58% and 37%, respectively. The insulin level of the normal and diabetic mice 
was not increased after the injection of HE-CS and HE-CI and thus their 
hypoglycemic mechanism was not mediated through the stimulation of insulin 
secretion. 
The significant in vitro inhibition of glucose diffusion and a-amylase activity by 
HE-CI, and the potent hypoglycemic effect of HE-CS and HE-CI in normal and 
diabetic mice suggested the potential use of these HE-polysaccharides as an 













中，並提出一種不能溶於冷水中的猴頭多糖 (HE-CI ) °HE-CS和HE-CI在大型熱 
水提取中的提取量為2 .34%和1 .87%�從結構分析當中，得出的HE-CS是主要由 
(1今6)鍵的葡聚糖所組成°而HE-CI主要的構成成份則是（1今3)鍵的葡聚糖。 
「血糖擴散阻礙指數」（GDRI)是用來測試HE-CS與HE-CI阻擋血糖擴散能力的 
試管實驗。在是次實驗中，由實驗開始後的 2 0分鐘直至完結，點性較高的H E - C I 
能有效地降低血糖擴散。其間最高的指數是在第9 0分鐘的4 5 . 0 2 �同時H E - C I 
亦具有抑制a-殿粉g每素活性的能力。在測試猴頭多糖對a-殿粉酶素影響的實驗 
中 ’ H E - C I能在實驗後的 2 0分鐘有效地將 a -殿粉_素的活性減低 8 6 % �在實 






在 l O O m g / k g注射劑量當中 ’ HE-CS在注射後的6小時，能將血糖最高降低至未 
注射前血糖量的56%�而HE-CI的最高降 i r糖能力，是在注射後的24小時，血 
糖為未注射前的41%�在糖尿病小鼠的測試中，腹腔注射200mg/kg劑量的HE-CS 
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Chapter 1 Introduction 
1.1 Diabetes Mellitus 
The word diabetes originates from Greek, meaning siphon; and mellitus is a 
Latin for honey. Originally, they mean the passage of excess amount of sweet 
urine (Tuch et al., 2000). Diabetes mellitus is an incurable chronic disorder, 
resulted in abnormally high fasting and non-fasting plasma glucose level. If the 
conditions of diabetes are not manipulated, it will lead to several serious 
complications such as retinopathy, nephropathy, neuropathy, diabetic foots, etc. 
1.1.1 Epidemiology 
Diabetes mellitus has been accepted as a growing global epidemic by many 
health advocacy groups including World Health Organization (WHO). The 
diabetes statistics results were worrying; 30 million people were diagnosed with 
diabetes worldwide in 1985; the number dramatically increased to 135 million 
people in 1995. Assuming that the rate of increase of diabetes remains the same, 
there will be a total of 300 million diabetic patients in 2025, predicted by the 
WHO. 
In U.S., the number of people diagnosed with diabetes was only 5.76 million in 
1980 and was moderately increased to 6.71 million in 1990. In 2002, the number 
reached to a peak of 13.30 million. Figure 1.1 showed the diabetic population 
from 1980 to 2002; the increase in diabetic population was tremendous in the 
years 1997-2002. Currently, there are more than 17 million type 2 diabetic 
1 
patients in US (about 5.9% of total population), 11 million in Europe, and 6 
million in Japan. 
；1 
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Figure 1.1 The trend of diabetic population in U.S. from 1980-2002 (from 
National Center for Chronic Disease Prevention and Health Promotion, 
2004) 
Two large-scale population-based epidemiological studies which employed the 
WHO diagnostic criteria for diabetes mellitus were performed in Hong Kong in 
1990 (Cockram et ah, 1993) and 1995 (Janus, 1997). In the study by Cockram, a 
total of 1513 subjects, recruiting from 2 workforces aged between 28-65, were 
surveyed. The aged-adjusted prevalence of diabetes mellitus was about 7.7%, of 
which the crude prevalence rose from less than 1% in subjects younger than 30 
years to more than 20% in the middle-aged group. The study in 1995 involved 
2900 subjects aged between 25-74, with an age-adjusted prevalence of 8.5%. The 
crude prevalence ranged from 1.7% in the age group of 25-34 to over 25% in the 
subjects older than 65. Due to different sampling methods, the data from these 2 
studies could not be used for direct comparison, but they supported the increase 
in diabetic population in Hong Kong. In both researches, only 30% of the 
2 
subjects had been previously diagnosed with diabetes, while the remaining were 
unaware of their hyperglycemic conditions. 
1.1.2 Economic Impact 
Diabetes not only deteriorates the health conditions of patients, it also brings 
considerable economic impact to the society. Substantial costs to the society and 
individuals are incurred for the direct and indirect cost of diabetes. Direct costs 
of diabetes include physician service costs, hospital service costs, long-term care 
costs, medication, laboratory, and other costs for therapy and management; while 
indirect costs are productivity lost due to short-term morbidity and productivity 
lost due to permanent disability and premature mortality. In 1980s, economic 
studies suggested that the total costs associated with diabetes in U.S. were 
between $14 billion and $20 billion in 1980s-era dollar, with an estimate of 
$7.4-$ 11.6 billion on direct medical care expenditure and an additional of 
$6.3-$ 10.8 billion dollar on the lost of productivity (Javitt and Chiang, 1995). 
Diabetes is not only a personal issue, it also affects the society in the long term. 
Hence it is worthy to acquire a better understanding of this disease. In the 
following section, the carbohydrate metabolism, the primary metabolism affected 
by diabetes, will be discussed, followed by the pathophysiology of type I and 
type II diabetes. 
3 
1.2 Digestion, Absorption and Metabolism of Carbohydrates 
1.2.1 Carbohydrate Digestion 
Figure 1.2 shows the carbohydrate digestion process. The aim of digestion of 
complex carbohydrates in food is to breakdown the digestible polysaccharides, 
e.g. starch, into monosaccharides by various digestive enzymes for subsequent 
absorption. The digestion of carbohydrate mainly occurs at two sites of the 
gastrointestinal tracts: mouth and small intestine. 
Foods are broken into smaller pieces by chewing action in the mouth and by the 
salivary enzyme amylase secreted from the salivary glands, hydrolyzing starch 
into shorter chains. 
In order to provide an optimum pH for protease in the stomach, pepsin, to 
function, the stomach secretes hydrochloric acid to acidify the environment. 
However, the acidic environment inactivates the salivary amylase and so the 
enzymatic breakdown of polysaccharides is terminated in the stomach. Despite 
this, hydrochloric acid is able to hydrolyze polysaccharides to a small extent. 
The small intestine is the place where the digestion of carbohydrate is completed. 
The exocrine gland of the pancreas secretes pancreatic amylase to the small 
intestine via the pancreatic duct to help digesting starch into shorter chains and 
maltose. The membranes of the intestinal cells secrete specific enzymes to 
breakdown disaccharides. These include maltase to hydrolyze maltose into two 
glucoses; sucrase to hydrolyze sucrose into one glucose and one fructose; and 
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Figure 1.2 The Digestion of Carbohydrates in the Gastrointestinal Tract 
(adapted from Whitney et al., 2002) 
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lactase to hydrolyze lactose into one glucose and one galactose. All the glucose is 
ready for absorption and assimilation of the body; fructose and galactose are 
finally converted into glucose by the liver after absorption (Barasi, 2003; 
Berdanier, 2000; Whitney et al., 2002). 
1.2.2 Carbohydrate Absorption 
After breaking down the dietary carbohydrates into monosaccharides, they are 
ready for absorption. Absorption mainly occurs in the small intestine but the 
mouth lining also contributes to a small extent of the absorption of glucose. 
Glucose and galactose pass into blood vessels in the villi on the surface of the 
small intestine by active transport while fructose requires facilitated diffusion to 
transverse the cell lining. Then glucose, galactose and fructose are transported to 
the target organs by the circulatory system (Barasi, 2003; Berdanier, 1995; 
Whitney et al., 2002). 
1.2.3 Insulin Secretion 
The absorption of glucose after a meal increases the blood glucose level which is 
tightly regulated in the body. Glucose level over about 180 mg/dL is associated 
with immediate effects such as glycosuria and calorie loss as well as chronic 
effects like renal failure (Ludwig, 2002). Thus insulin is secreted from the 
pancreas to suppress the rise in blood glucose. It increases rate of blood glucose 
transport across the cell membrane in adipose tissue and muscle as well as rate of 
glycolysis in muscle and adipose tissue. Insulin also stimulates rate of glycogen 
synthesis in several tissues including adipose tissue, muscle and liver, and 
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inhibits rate of glycogenolysis in adipose tissue, muscle and liver and 
gluconeogenesis in liver. Simultaneouly, insulin also promotes lipogenesis and 
protein systhesis and decreases their rate of breakdown (Dimitriads et al., 2000). 
All these mechanisms can effectively lower the postprandial blood glucose level. 
1.3 Pathophysiology of Diabetes Mellitus 
Diabetes mellitus is an incurable disease characterized by a high blood glucose 
level and several long-term complications originating from the damage to blood 
vessels, nerves, kidneys, and eyes. It can be classified into 2 types: 
insulin-dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes 
mellitus (NIDDM). The underlying causes of these 2 kinds of diabetes differ and 
require different treatments. 
1.3.1 Insulin-Dependent Diabetes Mellitus (IDDM) 
Insulin-dependent diabetes mellitus, also known as type I or juvenile-onset 
diabetes is featured by loss of p-cells in pancreas. Thus the patients are unable to 
produce insulin to manipulate the postprandial blood glucose level. Genetic 
factors and autoimmunity are known to be the 2 major factors for the 
development of IDDM. 
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1.3.1.1 Genetics 
The susceptibility of individuals to type I diabetes is inherited. The main gene 
predisposed to type I diabetes was found in the major histocompatibility complex 
(MHC) on chromosome 6. It was located in the region with the gene for the 
recognition molecules known as human leukocyte antigen (HLA), of the highly 
polymorphic immune system. The function of HLA is to present antigenic 
peptides to T-cells. It can be classified into class I and II, which have structural 
variations and locate on different cell types. Class I HLA is found on the surface 
of all nucleated cells and platelets, which presents the antigenic peptides to CDS 
T lymphocyte. Class II HLA is expressed either constitutively on dendritic cells 
and B lymphocyte or inducibly on macrophages and endothelial cells; it presents 
the antigenic peptide to CD4 T lymphocyte (Atkinson and Maclaren, 1994). HLA 
class II molecules have 3 sub-classes: HLA-DP, DQ, and DR; and it is the 
genotype of HLA-DR and HLA-DQ which are related to the susceptibility or 
resistance of IDDM (Todd and Bain, 1992). Two hypothesis were suggested to 
explain the relationship of the above 2 genotypes to type I diabetes. They may 
affect the degree of immune response to the pancreatic P-cell autoantigen and 
result in a vigorous P-cell damage (Nepom, 1990)，or the HLA molecules present 
the P-cell autoantigen to the lymphocyte without the normal immunologic 
tolerance (Sheehy, 1992). 
However, from other researches on the diabetic incidence of monozygotic twins, 
genetic composition is not solely responsible for the incidence of type I diabetes. 
Other factors also have contribution in it. 
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1.3.1.2 Autoimmunity 
According to Atkinson and Maclaren (1994), the immune system could attack the 
pancreatic P-cells through the following pathways as depicted in figure 1.3. An 
immune response against a viral protein with the same amino acid sequence of 
the P-cell protein such as coxsackievirus protein and glutamate carboxylase could 
activate the antiviral cytotoxic CDS T lymphocyte to cross-destroy the protein on 
the P-cells. Alternatively, infection of the P-cells could induce the release of the 
cytokines and other inflammatory mediators that induce the expression of 
adhesion molecules in the vascular endothelium of the pancreatic islets. The 
activated endothelial cells would permit increased adhesion and extravasation of 
circulating leukocytes and the presentation of P-cells antigens from the damaged 
(3-cells by infiltrating macrophages to lymphocytes (Atkinson and Maclaren, 
1994). 
For both destructive pathways, the continued release of inflammatory cytokine 
from the damaged islets could lead to the overexpression of HLA class I 
molecules on p-cells, further enhancing the destruction. When the immune 
response was initiated, various effectors immune mechanisms such as 
antibody-dependent cellular cytotoxicity, delayed hypersensitivity, complement 
activation, and the production of cytotoxic concentration of cytokines, could 
invade the (3-cells which resulted in a permanent loss of insulin-producing 
activity (Atkinson and Maclaren ,1994). 
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1.3.2 Non-Insulin-Dependent Diabetes Mellitus (NIDDM) 
Non-insulin-dependent diabetes mellitus is also known as type II or adult-onset 
diabetes. Differing from type I diabetes, type II diabetes does not start with a 
complete lack of insulin to manipulate the blood glucose; in contrast, the insulin 
level of type II diabetic patients is higher than normal. In most circumstances, 
NIDDM usually begins with impaired sensitivity of the tissue to insulin; then as 
the tissue insulin resistance develops and increases in progress, the insulin 
secretion is affected. Therefore insulin resistance and impaired insulin secretion 
work in a synchronized manner leading to the development of overt type II 
diabetes mellitus (Bergman et al., 2002; Boden and Shulman, 2002; Gerich, 1999; 
Roden et al, 1996). 
1.3.2.1 Insulin Resistance 
Glucose homeostasis is dependent upon three interrelated routes: (1) suppression 
of hepatic glucose production; (2) increase of splanchnic (hepatic and 
gastrointestinal) glucose uptake; (3) stimulation of glucose disposal by peripheral 
tissues, mainly muscles. Thus, if the tissue involved in these routes, such as liver, 
have impaired insulin sensitivity, they are resistant to insulin and so can not 
dispose excess glucose in response to insulin. This phenomenon is also termed as 
insulin resistance. According to DeFronzo (1992), it was the resistance developed 
in the hepatic glucose production and glucose disposal by peripheral tissues that 
contributed to the elevation of blood glucose level and initiated type II diabetes. 
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Suppression of hepatic glucose production 
DeFronzo groups showed that the liver of a healthy subject produced glucose at a 
rate of about 1.8-2.2 mg/kg/min in the post-absorptive state. Type II diabetic 
patients with moderate fasting hyperglycaemia showed a consistent increase in 
basal hepatic glucose production at 0.5 mg/kg/min (DeFronzo, Ferrannini and 
Koivisto, 1983; DeFronzo et al” 1985; DeFronzo and Ferrannini, 1987; Groop， 
Bonadonna and Del Prato, 1989). When extrapolated over 24 h, a 70-kg type II 
diabetic patient would generate an additional 50 g of glucose every day. 
Simultaneously, the plasma insulin increased 2-3 times in the type II diabetic 
subjects. One of the functions of insulin is to suppress the hepatic glucose 
production and from the above results, it was clear that insulin resistance had 
developed in liver and resulted in the overproduction of glucose in liver. 
Utilization of glucose by peripheral tissue (muscle) 
DeFronzo and colleagues (1985) proved that muscle tissue was the primary site 
of insulin resistance, by using the insulin clamp technique with femoral 
vein/artery catheterization to study the glucose dynamics in leg muscle. In 
normal subjects, the glucose uptake in leg in response to insulin had increased for 
10 times; however, in type 2 diabetic patients, the leg glucose uptake was 
delayed and significantly reduced by 40-50%. 
The study conducted by DeFronzo, Ferrannini and Simonson (1989) clearly 
illustrated the relationship between plasma glucose, plasma insulin, hepatic 
glucose production and glucose clearance. Figure 1.4a showed the result of 
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overnight insulin infusion to normalize the hepatic glucose production. Despite 
similar glucose production in normal and type II diabetic subjects, the insulin 
level of diabetic patients was much higher. They also had a higher level of 
plasma glucose due to an ineffective rate of glucose clearance. 
Figure 1.4b was the result of overnight insulin infusion to normalize the plasma 
glucose. The diabetic patients needed to secrete 2 times more insulin to lower the 
elevated glucose level. And due to lower rate of glucose uptake by the tissue, i.e. 
glucose disposal, the rate of glucose clearance was inevitably lower in type II 
diabetes patients. 
1.3.2.2 Impaired Insulin Secretion 
Once the liver and muscle tissues are resistant to insulin, glucose tolerance 
remains normal. The normalization of plasma glucose level and the hepatic 
glucose production can be achieved by increasing the insulin secretion as shown 
in figure 1.4. The increase in the severity of insulin resistance will augment the 
insulin secretion by p-cells in order to maintain normal glucose homeostasis. The 
onset of diabetes is associated with the reduction of insulin secretion, thus the 
plasma glucose increases. The progression of mild to severe diabetes is due to 
further reduction in insulin secretion and thus worsening plasma glucose control. 
The reduction of insulin secretion is known as P-cell exhaustion (Lingappa and 
Farey, 2000; Zraika et al., 2002). 
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1.4 Management of Diabetes Mellitus 
In order to prevent further complications of diabetes mellitus, blood glucose level 
of diabetic patients should be properly manipulated. For type I diabetes, due to 
the loss of ability to secrete insulin to suppress blood glucose level, injection of 
exogenous insulin is required for blood glucose manipulation. For type II 
diabetic patients, diet modifications and physical activity are two common ways 
for the patients to decrease elevated blood glucose level. However, if they are 
ineffective, the patients will need to prescribe hypoglycemic agents to lower the 
blood glucose level. The main functions of these hypoglycemic agents are (1) 
enhancement of insulin secretion; (2) reduction of hepatic glucose output; and (3) 
improvement in peripheral insulin sensitivity (Brown and Brillon, 1999). The 
two most common hypoglycemic drugs are sulfonylureas and biguanides. 
1.4.1 Sulfonylureas 
Sulfonylureas are the derivatives of sulfonic acid and urea. They suppress 
glucose level in type II diabetic patients by stimulation of insulin secretion. They 
produce their effect by binding to the surface of pancreatic p-cells; the binding 
will depolarize the cell membranes leading to the influx of calcium ion, and 
subsequently the release of insulin. Sulfonylureas consist of two generations of 
agents and the second generation is more commonly prescribed as they are more 
effective and safer (Brown and Brillon, 1999; Wagman and Nuss, 2001). 
15 
1.4.2 Biguanides 
Metformin is the only biguanide currently approved for the treatment of type II 
diabetes. It mainly inhibits the increase in hepatic glucose production which is a 
common symptom in type II patients. Metformin interferes with several 
processes which are associated with hepatic glucose production such as 
gluconeogenesis, glycogenolysis and their regulatory mechanisms, and thus 
lowers the glucose production and resensitizes the liver to insulin. It also reduces 
the intestinal absorption of glucose and increases glucose sensitivity, resulting in 
increased peripheral glucose uptake and utilization (Wagman and Nuss, 2001). 
In recent years, newer hypoglycemic agents are developed with improved 
efficacy and safety profiles. In addition, various biological targets are being the 
focus of hypoglycemic drugs. They include (1) insulin sensitizers such as protein 
tyrosine phosphatase-IB and glycogen synthase kinase; (2) inhibitors of 
gluconeogenesis like pyruvate dehydrogenase kinase; (3) lipolysis inhibitors; (4) 
fat oxidation including carnitine palmitoyltransferase I and II inhibitors; and (5) 
energy expenditure by beta 3-adrenceptor agonists (Wagman and Nuss, 2001). 
1.4.3 Problems Encountered in the Management of Diabetes 
As mentioned above, the blood glucose level of diabetic patients should be 
properly managed to prevent the onset of other complications. However, both the 
use of exogenous insulin in type I patients and hypoglycemic drugs in type II 
patients are associated with side effects. 
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The most common problem of the use of insulin in type I diabetic patients is 
hypoglycemia, i.e. more than required insulin is injected, causing substantial 
reduction in blood glucose level. The hypoglycemic status occurs when the blood 
glucose level falls below 2.5 mmol/L, but in some cases, it may also happen 
between 3-4 mmol/L (Tuch et al., 2000). In many insulin-treated patients, the 
perception of hypoglycemic symptoms becomes altered or diminished, and they 
develop clinically recognized problem of impaired awareness of hypoglycemia. 
This is related to progression to more severe hypoglycemia, and has an attendant 
morbidity (McAulay et al., 2001). 
For commonly prescribed hypoglycemic drugs, not only will they cause 
hypoglycemia when the dose is excessive, they also have other side effects. For 
instance, sulfonylureas may lead to hypoglycemia as their effect may still persist 
even when insulin is not required. The use of it may also cause weight gain. 
Chronic usage of sulfonylureas may also exacerbate pancreatic p-cell exhaustion 
due to over stimulation of insulin secretion; and the main complication of 
metformin is lactic acidosis (Wagman and Nuss, 2001; Brown and Brillon, 
1999). 
In a study conducted by Yap and colleagues (1998)，150 type II diabetic patients 
with an average age of 70 士 11.8 years were surveyed for their habit of using 
hypoglycemic drugs. The results showed that of the 45 patients using 
glibenclamide which belongs to the sulfonylurea family, 40 (about 88.9%) had 
one or more risk factors for developing hypoglycemia: over 65 years old, renal 
impairment, or cognitive impairment and living alone. The study also discovered 
that patients using metformin had one or more contra-indication of using it and 
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are at the highest risk of developing lactic acidosis. Sixty-six patients out of 70 
using metformin had at least one contra-indication according to manufacturer 
information; 57% had two to three contra-indications while 14% patients had 
more than three. The more common contra-indications were angina, chronic use 
of diuretics, cardiac failure, and the presence of hypoxia. The misutilization of 
these two drugs and failure to adopt a more appropriate treatment increase the 
risk of hypoglycemia for glibenclamide and developing lactic acidosis, especially 
in elderly patients. 
As the use of insulin and hypoglycemic drugs are both associated with 
considerable side effects, the necessity for searching a new kind of diabetic 
treatment with high efficacy and improved safety is obvious. 
1.4.4 Role of Dietary Fiber in the Management of Diabetes Mellitus 
Dietary fiber has been recommended to be incorporated into the diet of diabetic 
patients for the management of blood glucose level. Blackburn et al. (1984a and 
1984b) and Jenkins et al. (1977 and 1978) proved that the consumption of dietary 
fiber could effectively improve glucose tolerance. Viscous polysaccharides such 
as guar gum added to the diet of normal or diabetic individuals can reduce 
postprandial glycemic response to a meal (Jenkins et al., 1977; Goulder et al” 
1978). The lowering of blood glucose absorption by dietary fiber is believed to 
be linked to digestion and transit time in the stomach and small intestine. 
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1.4.4.1 Dietary Fiber and Gastric Emptying Time 
Soluble fiber, which can increase the viscosity of gastric content, can reduce 
glucose absorption by delaying gastric emptying time, and thus limit the quantity 
of digesta delivered to the active absorption site of glucose in the small intestine 
(Blackburn et al., 1984a; Holt et al., 1979; Torsdottir et al., 1989). In the studying 
the dynamics of gastric emptying, emptying of viscous solution was associated 
with higher antral pressure than emptying of a watery solution (Bueno et al. 
1981). Despite this, antral contractions of viscous solution indented the gastric 
lumen to a lesser extent (Prove and Ehrlein, 1982). From these results, Read and 
Eastwood (1992) suggested that higher pressure was recorded in the presence of 
viscous polysaccharides because they resisted propulsion through the pylorus, 
and such resistance resulted in a decrease in antral indentation. 
However, the effect of viscous polysaccharides on gastric emptying time also 
depends on the nature of food components. Inclusion of guar gum in meals 
containing discrete solid and liquid components delayed the emptying of liquids, 
but accelerated the passage of solid particles (Meyer et al., 1986). Under normal 
circumstances, solids are retained in the fundus of the stomach until the majority 
of liquid are emptied. Then they enter the antrum and are disintegrated by antral 
contraction until they are light enough to be passed through the pylorus (Meyer 
et al., 1986). Increasing the viscosity of gastric contents prevented the separation 
of solid and liquid components. Thus, the solid particles transit into the small 
intestine simultaneously with the liquid components (Meyer et al” 1986). Despite 
acceleration of transit of the solid matter, its digestion would not be increased, 
but rather inhibited. This was because reduction in retaining time of solid 
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particles in the stomach decreased the surface area for the digestive enzymes to 
work on. 
In spite of available evidence to show the relationship of viscous polysaccharides 
and gastric emptying time, other results demonstrated that such relationship was 
not absolute. No correlation was found between the half emptying time or gastric 
emptying rate and glycemic and insulinaemic responses in healthy subjects 
ingesting an oral glucose load with different type of viscous fiber at various 
doses (Jarjis et al., 1984; Edwards et al., 1987). In addition, similar effect of guar 
gum was observed in healthy and partially gastrectomized subjects (Lembcke et 
al” 1984). Although there is no doubt that gastric emptying time has contribution 
to delaying the absorption of glucose, whether it is a major factor remains a 
controversial issue. 
1.4.4.2 Dietary Fiber and Glucose Absorption in Small Intestine 
Contraction of the gastrointestinal tract, i.e. gastrointestinal motility, causes 
mixing that increases the access of the food substrate to digestive enzymes and 
facilitate the transport of absorbable products to the epithelium of gastrointestinal 
tract (Read and Eastwood, 1992). 
Perfusion of loops of small intestine of rat or human in vivo with glucose solution 
showed that viscous polysaccharides decreased glucose absorption and such 
effect was directly related to the viscosity of polysaccharides (Blackburn et al., 
1984b; Elsehans et al., 1981; Johnson and Gee, 1981). The role of viscosity of 
polysaccharides in delaying glucose absorption was explained by ‘‘unstirred 
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water layer". The concept of unstirred water layer is that water becomes more 
structured and less mobile where it is very close to the solid-liquid interfaces. 
Thus the unstirred water layer that lies immediately adjacent to the intestinal 
epithelium can be regarded as a water layer that the substrates have to diffuse 
across to reach the cell membrane of the small intestine (Read and Eastwood, 
1992). The thickness of the unstirred water layer is affected by intestinal 
contraction and is inversely related to the magnitude of stirring rate. When 
contraction in the small intestine is minimized, fluid moves through it by laminar 
flow with no movement in radial direction (from the center towards the 
epithelium). Consequently, stirring is poor and the unstirred water layer is 
relatively thicker. On the other hand, normal gastrointestinal motility gives 
contraction in longitudinal and radial directions, and thus creates turbulence and 
stirring of intestinal content. Under such situation, the unstirred water layer is 
thinner (Cherbut, 1995). 
In the presence of viscous polysaccharides such as guar gum, intestinal motility 
was stimulated but transit rate was lowered because the viscous nature of dietary 
fiber was resistant to propulsive contraction (Cherbut, 1995). At the same time, 
the viscous fiber should similarly resist mixing contraction, and the thickness of 
unstirred water layer was increased due to a decline in the level of mixing 
(Elsenhans, Zenker & Caspary，1984; Johnson and Gee, 1981). Therefore, the 
absorption of glucose was lowered due to the presence of a thick water layer to 
block effective glucose absorption. 
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1.4.5 Other Natural Products used for Diabetes Treatment 
Plant products have long been used for the treatment of diabetes. For example, in 
northern Europe, burdock, cashew, dandelion, elder, and fenugreek etc. are some 
traditional common herbs used for diabetes (Swanston-Flatt et al., 1989). In 
Mexico, the study by Alarcon-Aguilara and colleagues (1998) found that several 
traditional plants used for diabetes could significantly reduce the hyperglycemic 
peak in glucose tolerance test on rabbits. These plants included golondrina, 
guacima, salvia, platano, mangle rojo, fenogreco, lagrimas san pedro and 
damiana. In fact, quite a lot of traditional natural products used in traditions such 
as Gymnema sylvestre from India (Xie et al” 2003), karela (bitter melon) in Asia 
(Leatherdale et al., 1981) and Urtica pilulifera in Europe (Kavalali, 2003), have 
been proved for their antidiabetic efficacy. Mushroom is one of the plant 
products that offers promising antidiabetic effects. 
1.5 Mushrooms 
Mushrooms have long been recognized as a valuable food source; truffles, for 
example, are one of the most expensive mushrooms in the West (Sadler, 2003); 
while Lentinus edodes (or known as shiitake in Japan) is the most common 
edible mushroom in China and Japan. In Western countries, the earliest record of 
dietary consumption of mushrooms could be traced back to the Greeks and 
Romans. China also has a long history of utilizing mushrooms in food and herbal 
preparation. Historians suggested that such practice could possibly begin in the 
Yaoshao culture, 6,000-7,000 years ago, in the Neolithic period (Benjamin, 
1995a). Besides its palatability, the medicinal usage of mushrooms cannot be 
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neglected. For instance, in Russia, an extract from Chaga {Inonotus obliquus) is 
used as an antitumour medicine and diuretic (Wasser and Weis, 1999). While 
there were enormous records of using mushrooms in herbal preparation, the 
earliest one was ‘‘Shen Nong's Herbal” (Shen Nong Pen Ts'ao Jing) in 
100-200AD. It documented the medicinal functions of Ganoderma lucidum, 
Poria cocos, Polyporus umbellatus, Omphalia lapidescens and other fungi. In 
Ming Dynasty, the famous herbalist, Li Shi-Zhen, had composed the famous 
herbal record "Pen Ts'ao Kang Mu’，，in which several medicinal usages of fungi 
and mushrooms such as Polyporus umbellatus, Polyporus mylittae, Lentinus 
edodes, Auricularia auricula and Tremella fulciformis etc. were listed (Ooi, 
2000). 
With advance of scientific technology, several researches on the pharmacological 
activities of fungi and mushrooms confirmed that mushrooms or their related 
products had the following significant medicinal properties: immunomodulatory, 
anti-cancer, antiviral, antimicrobial, antioxidative and free-radical scavenging, 
liver protective, antifibrotic, anti-inflammatory, antidiabetic and hypoglycemic as 
well as hypoglycemic effects (Ooi and Liu, 1999). 
1.5.1 The Definition of Mushrooms 
Fungi are neither plants nor animals. They lack chlorophyll to convert the solar 
energy into their own food source，and thus they rely on the following method to 
sustain their life. They may act as a decomposer or known as saprobes, living on 
dead or decaying organic material. Some species of fungi also adopt a parasitic 
mode of life; they live by causing harm to their host. And the final mode of living 
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is symbiosis; some fungi develop certain association with the roots of many 
plants, especially trees (Benjamin, 1995b). 
Mushroom is a certain kind of fungi. In some circumstances, mushroom is only 
used to describe the reproductive organ of a fungus. However, it is also used to 
refer to any fungus that bears a fleshy fruiting body. In a more restricted sense, it 
only includes the fleshy fiingi with the fruiting bodies bearing spores on radiating 
blades called gills (Arora, 1986). According to Chang and Miles (1992)， 
macrofungi with distinctive fruiting bodies, which are large enough to be seen 
with naked eye and to be picked by hand, have been referred to as mushrooms. It 
had been reported that 12,000 species of fungi could be considered as 
mushrooms, while only 50% of these mushrooms possess varying degree of 
edibility (Miles and Chang, 1997). Most of the mushrooms belong to the class 
Basidiomycetes but also a few others from the class Ascomycetes (Chang, 
1999a). The Ascomycetes are characterized by the formation of ascospores 
within specialized hyphal segments or cells, known as ascus which is the 
common site of nuclear fusion and meiosis. Basidiomycetes are characterized by 
the formation of spores on differentiated hyphal tips (basidia), which are usually 
the site of nuclear fusion and meiosis (Griffin, 1994). 
1.5.2 Nutritional Values of Mushrooms 
The moisture content of fresh edible mushrooms varies from 70 to 95%, 
depending on harvest time and environmental conditions; and it can be reduced 
to about 10 to 13% in dried mushrooms. It has been estimated that the average 
protein content of mushrooms was 3.5 to 4% by fresh weight. Such value was 
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higher than other common botanical foods like onion (1.4%); cabbage (1.4%); 
orange (1.0%) and apples (0.3%). Moreover, mushrooms contain all the nine 
essential amino acids required by human including histidine, isolecine, leucine, 
lysine, methionine, phenylalanine, tryptophan, threonine and valine (Chang, 
1999a). 
Mushrooms are also a good source of minerals and vitamins with their amounts 
varied with the growth substrate. They can supply phosphorus, potassium, 
selenium, zinc, magnesium, copper and B vitamins. For instance, raw button 
mushrooms can provide 0.6 mg iron and 0.72 mg copper per 100 g by fresh 
weight. 
Huang and colleagues (1989) reported that commonly cultivated mushrooms had 
a total lipid level ranged from 0.6 to 3.1% of dry weight, with at least 72% of 
total fatty acids being unsaturated. 
Besides protein and lipid, mushrooms also have a high level of dietary fiber 
including，chitin, P-glucan, heteroglycan and proteoglycan. Some of which 
possess different pharmacological benefits as mentioned in 1.5. 
1.5.3 Production of Mushrooms 
Due to a high-quality protein profile, a high proportion of unsaturated fatty acids, 
and a high level of health-promoting fiber, mushrooms can be regarded as an 
ideal food source and alternative herbal medicines in century. Thus the 
cultivation of mushrooms, including edible and medicinal, have tremendously 
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increased in recent years. Table 1.1 shows the global production of mushrooms in 
different periods. In 1981, the total mushrooms production was 1,257.2 x 10^ 
tons while the number increased to 2,182.0 x lO^in 1986, with a 73.6% increase. 
Due to sophisticated technology in mushroom science and cultivation, the 
mushroom production increased to 6,158.4 x 10^ tones in 1997; when compared 
to 4,909.3 tons in 1994，the increase was about 30.5%. From table 1.1, Agaricus 
bisporus and Lentinus edodes are the two mains mushrooms being cultivated; 
however, the proportion of A. bisporus has decreased from 71.6% in 1981 to 
31.8% in 1997. The cultivation of L edodes was gaining importance, with 

















































































































































































































































































































































































































































































1.6 Medicinal (Antidiabetic) Properties of Mushrooms 
Due to a long historical record of medicinal use of mushrooms in the treatment of 
different diseases, it is worthy to conduct a systematic study of various medicinal 
properties of mushrooms and their biologically active components. From most of 
the researches and clinical trials, fungal polysaccharides is one of the bioactive 
molecules giving stable pharmacological functions of mushrooms such as 
antitumour activity (Ooi and Liu, 1999). Polysaccharides are structurally diverse 
macromolecules of relatively widespread occurrence in nature. Polysaccharides 
are built up of repetitive monosaccharides which are linked by glycosidic 
bonding. Due to the structural variability, polysaccharides have the highest 
capacity to convey the biological information than other biomolecules such as 
protein and nucleic acids. Such structural specialty enables polysaccharides to 
play a role in the cellular regulations in higher organisms (Ooi and Liu, 2000). 
Among all the pharmacological activities, fungal polysaccharides offer the most 
promising immunomodulatory and antitumour effects. However, recent studies 
revealed that fungal polysaccharides could ameliorate high blood glucose level in 
diabetic murine model and improve their health conditions. In the following, the 
antidiabetic function of polysaccharides isolated from several mushrooms will be 
discussed. 
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As diabetes is gaining prevalence in the global population, it is necessary to find 
new kinds of treatment and preventive measures to lessen the severity of this 
disease. Mushrooms are ideal alternatives to be studied for their antidiabetic 
action. Several mushrooms have been found with antidiabetic or hypoglycemic 
functions; they are Ganoderma lucidum, Tremella aurantia, Grifonla frondosa 
and Auricularia auricula’ etc. 
1.6.1 Ganoderma lucidum 
Ganoderma lucidum, known as Lingzhi in China or Reishi in Japan, has been 
recognized for long time in history; it is a symbol of health, wealth, longevity 
and even immortality. The antidiabetic function of G. lucidum was found in 
1980s. According to Kimura et al. (1988), a water extract from G. lucidum could 
suppress the rise in both blood glucose and lower the insulin peak level in rats 
after glucose infusion in an oral glucose tolerance test (OGTT). This water 
extract of G. lucidum inhibited the reduction in the plasma insulin level in rats 
during 20 and 60 min, and thus the insulin level of the rat was higher than that of 
control, which stared to drop 10 min after the glucose infusion. 
Further fractionation of this hypoglycemic extract had found that the active 
hypoglycemic components were two polysaccharides, designated as ganoderans 
A and B. Not only could they reduce plasma glucose level in normal mice, but 
also in alloxan-induced diabetic mice. The injection of ganoderan A at 100 mg/kg, 
i.p. suppressed the blood glucose level significantly in normal mice to about 48% 
of pre-injected blood glucose level 7 h after administration, and to 46% in 
diabetic mice; while ganoderan B at the same dosage and time period could 
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reduce the plasma glucose to 57% and 49% in normal and diabetic mice, 
respectively (Hikino et al., 1985). Tables 1.2 and 1.3 show the antidiabetic effect 
of ganoderans A and B in normal and diabetic mice. 
By gel chromatographic separation using Sephacryl-200, the molecular weightd 
of ganoderan A and B were found to be approximately 2.3 x and 7.4 x 10^ 
respectively. Ganoderan A is composed of the neutral sugar rhamnose, galactose 
and glucose in a molar ratio of 0.4:1.0:0.7; while mannose and glucose 
constitutes ganoderan B in a molar raito of 0.05:1.0. It also has galacturonic and 
glucuronic acid (0.7:1.0) as acidic sugar component. Ganoderan A has little 
protein moiety (about 2.6%) while ganoderan B had a higher amount of protein 
(17.5%) (Hikino et al., 1985). 
A mechanistic study of the hypoglycemic action of ganoderan B had revealed 
that it stimulated the plasma insulin secretion in normal and glucose-loaded mice. 
It also enhanced the glucose breakdown by increasing the activity of hepatic 
glucokinase, phosphofructokinase and glucose-6-phosphate dehydrogenase; and 
decreasing the activity of hepatic glucose-6-phosphatase, all of which leading to 
an accelerated metabolism of plasma glucose (Hikino et al., 1989). 
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Table 1.2 Effect of Ganoderan A and B from G lucidum on Plasma Glucose 
Level in Normal Mice 
Relative glucose level (%) 
Dose 0 7 24(h)b 
Group  
(mg/kg, 
(n = 5) ma m 士 SE m ± SE % 
i'P) 
Control 100 101 土 5 100 104 ± 2 100 
Ganoderan A 10 100 56 土 3] 55 81 士 7 � 78 
30 100 60 士 2d 59 62 ±3^ 60 
100 100 48 士 4d 48 58 土 56 
Control 100 101 士 5 100 104 ± 2 100 
Ganoderan B 10 100 71 ± 8 � 70 90 士 4 � 87 
30 100 87 士 6 86 111 士 5 107 
100 100 57 土 4d 56 87 士 6 � 84 
a) Values represent means ± S.E. Each plasma glucose level at 0 h (140-170 
mg/dL) was adjusted to 100. b) Time after injection. Significantly different from 
the control using Student's /-test, c)/?< 0.05, d)j9< 0.01. e) Blood glucose level 
relative to the control (adapted from Hikino et al., 1985) 
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Table 1.3 Effect of Ganoderan A and B from G lucidum on Plasma Glucose 
Level in alloxan-induced diabetic Mice 
Relative glucose level (%) 
Dose 0 7 24(h)b 
Group  
(mg/kg, 
(n = 5) ma m 土 SE m 士 SE % 
ip) 
Control 100 87 士 4 100 85 士 8 100 
Ganoderan A 10 100 50 士 8 � 57 69 士 8 81 
30 100 45 士 6d 52 69 士 9 81 
100 100 46 士 5d 53 57 士 67 
Control 100 93 士 2 100 90 士 5 100 
Ganoderan B 10 100 83 士 4 89 90 ± 5 100 
30 100 72 士 5d 77 77 ± 6 86 
100 100 49 士 5d 53 69 士 77 
a) Values represent means 土 S.E. Each plasma glucose level at 0 h (250-450 
mg/dL) was adjusted to 100. b) Time after injection. Significantly different from 
the control using Student's /-test, c)p< 0.05, d)/?<0.01. e) Blood glucose level 
relative to the control (adapted from Hikino et al., 1985) 
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1.6.2 Tremella aurantia 
The fruiting bodies of T. aurantia have been used as food and medicine in China 
to cure symptoms such as hypertension and bronchial asthma. An acidic 
polysaccharide (TAP) extracted with hot water showed potent hypoglycemic 
effect in normal and both type of diabetic mice. In normal mice (5 week-old male 
ddY mice), the injection of TAP at 30, 50 and 100 mg/kg intraperitoneal reduced 
the blood glucose level significantly at 3, 6 and 24 h after administration. At a 
dosage of 30 mg/kg, the effect was the highest at 3 h after injection with a blood 
glucose level reduced to 72.3%. At 50 and 100 mg/kg, the most remarkable effect 
of TAP was found at the hour, with blood glucose level being reduced to 64.1 
and 62.5%, respectively. The hypoglycemic test result of TAP on normal mice 
was shown in table 1.4. The antidiabetic effect was more potent when testing on 
diabetic model. From table 1.5, after administration of TAP, the blood glucose 
level in type I diabetic mice (5 week-old male ddY mice induced by STZ) was 
reduced to 33.5% at hour; while for type II diabetic mice, the highest drop in 
blood glucose was also found at hour to 33.8% (Kiho et al., 1995). 
TAP also demonstrated an effective antidiabetic effect as well as other 
health-benefiting functions in a long-term study on KK-A^ mice which are 
genetically predisposed to NIDDM. TAP solution (0.5 g/L) was fed to the mice 
for 10 weeks. When compared to control，the elevation of blood glucose was 
depressed; at the same time, TAP also decreased the insulin, total cholesterol and 
triglyceride in the blood (Kiho et al., 2001). In another study by Kiho and 
colleagues (2002), the antidiabetic study of TAP solution (0.5 g/L) feeding to the 
KK-A^ mice was conducted. In this experiment, the blood glucose level of the 
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mice was already higher than the previous test, induced by high-calorie diet. 
Despite the high blood glucose level, TAP was still effective in lowering the 
blood glucose in mice and simultaneously reduced the total cholesterol, free 
cholesterol, free fatty acid and triglyceride, having an increase in the 
high-density lipoprotein cholesterol ratio. 
Further study on the effects of TAP on glucose metabolism had found that TAP 
increased the activities of glucokinase, hexokinase and glucose-6-phosphate 
dehydrogenase; decreased the activities of glucose-6-phosphatase in the liver of 
normal and diabetic mouse after intraperitoneal administration (Kiho et al., 
2000b). Therefore the metabolism of glucose was accelerated and resulted in 
increased rate of glucose disposal. 
Structural studies of TAP suggested that TAP is composed of mannose, xylose, 
glucuronic acid and glucose in a molar ratio of 4:2:1:0.3 (Kiho et al., 2000a). 
TAP consisted of a (1—3)-linked a-D-mannopyranosyl backbone, some of which 
was substituted with (l-^3)-linked |3-D-xylopyranose side chains at position 2 
and with P-D-glucopyranosyl-uronic acid at position 4 linked to terminal 
a-D-mannopyranose. Figure 1.5 shows the possible repeating structure of TAP. It 
was suggested that non-reducing terminal a-D-mannopyranosyl residues may 
contribute to remarkable antidiabetic activity (Kiho et al” 2000a). 
34 
Table 1.4 Effect of TAP on Plasma Glucose Level in Normal Mice after 
Intraperitoneal Injection 
_ Dose Relative plasma glucose level (VoY Group  
(n = 5 ) 帖 ， 0 3 6 24 48 (h)^  
Control 100 112.6 士 1.6 104.9 土 1.9 96.6 ±3.6 102.1 ±2.0 
TAP 30 100 72.3 ±2.6d 74.4 ±3.4] 82.7 ±2.7 ' 95.5 土 2.5 
50 100 70.3 土 1.id 64.1 士 3.2d 79.3 士 2.5' 94.7 ±4.4 
100 100 66.7 士 2.5d 62.5 士 3.4d 80.5 士 2 . 6 ' 97.8 士 3.3 
a) Values represent means 士 S.E. Each plasma glucose level at 0 h (170-210 
mg/dL) was adjusted to 100. b) Time after injection. Significantly different from 
the control using Student's Mest, c)p< 0.05, d)p< 0.01. (Adapted from Kiho et 
al., 1995) 
Table 1.5 Effect of TAP on Plasma Glucose Level in Diabetic Mice after 
Intraperitoneal Injection 
^ Dose Relative plasma glucose level Group  
(n = 5) (""g/kg’ 0 3 6 24(h)b 
i必 IDDM model' 
Control 100 87.4 ±2.0 85.1 士 3.3 87.7 士 3.3 
TAP 50 100 50.8 ±4.1 ' 33.5 ± 3.8^ 84.3 ±2.7 
NIDDM model^ 
Control 100 89.6 士 6.2 87.2 士 4.5 96.1 士 4.6 
TAP 50 100 36.6 士 1.7g 33.8 士 4.1厂 66.4 士 12.2 
a) Values represent means 土 S.E. Each plasma glucose level at 0 h (500-750 
mg/dL) was adjusted to 100. b) Time after injection, c) Streptozotocin-induced 
diabetic mice, d) KK-A^-TA mice. Significantly different from the control using 
Student's ,-test, e)/? < 0.01, f);? < 0.005，g)p< 0.001. (Adapted from Kiho et al., 
1995) 
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^ ^xA ^ y 
X : y: z = 2 : 2 : 3 
Man = a -D-mannopyranose 
Xyl = p -D-xylopyranose 
GlcA = P -D-glucuronic acid 
Figure 1.5 The structure of TAP (adapted from Kiho et al., 2000a) 
1.6.3 Auricularia auricula 
Auricularia auricula is also known as wooden ear in China. In traditional 
Chinese medicine, it is mild and sweet in flavor. It is used to cure hemorrhoids, 
to stimulate bowel movements, to help build up energy, and to act as 
anticoagulants, as well as to supply dietary fiber for the prevention of geriatric 
disorders (Ooi, 2000). 
An evaluation of the antidiabetic potency of the polysaccharide extracted with 
hot water from the fruiting body of A. auricula was conducted with genetically 
diabetic KK-A^ mice. A hot water-soluble polysaccharide, FA, could reduce the 
plasma glucose, insulin, urinary glucose and food intake when supplemented to 
the animal diet at a level of 30 g of FA per kilogram of diet. FA supplementation 
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also improved glucose tolerance to intraperitoneal glucose loading. The blood 
glucose level of the FA-fed group was significantly lowered at 30，60, and 120 
min after glucose injection i.p. The liver glycogen content of the mice was also 
increased (Yuan et al, 1998a). 
The water-soluble polysaccharides of A. auricula were further fractionated for 
subsequent study of their antidiabetic activities in the KK-A^ mice. They were 
found to be a mixture of crude polysaccharides (FA), consisting of acidic 
polysaccharide fractions (FA-A) and neutral polysaccharide fractions (FA-N). FA 
supplementation at 15 g per kilogram of diet retained the ability to reduce fasting 
and non-fasting blood glucose, urinary glucose, and food and water intake. While 
FA-N supplementation produced a does-dependent effect in lowering fasting and 
non-fasting blood glucose, insulin, urinary glucose and food and water intake, it 
did not improve glucose tolerance. The results also showed that FA-A 
supplementations have no beneficial effect in diabetic mice (Yuan et al., 1998b). 
1.6.4 Grifola frondosa 
G. frondosa has been frequently used for relieving stomach and spleen problems, 
calming nerves and mind, and treating hemorrhoids. It has also been reported to 
be effective in lowering blood pressure and cholesterol, and protecting the liver. 
The polysaccharides isolated from G frondosa have antitumour activity, 
especially effective against breast colorectal cancers (Ooi，2000). 
Water extract from the fruiting bodies of G frondosa depressed elevated plasma 
glucose and insulin levels in type II diabetic KK-A^ mice both in a one-month 
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(Kubo et al., 1994) and 7-day studies (Manohar et al., 2002). In the study 
conducted by Horio and Ohtsuru (2001), the antidiabetic activities of the whole 
fruiting body of G frondosa were evaluated with streptozotocin-induced type I 
diabetic rats. When the group of diabetic rats were fed with diet supplemented 
with 20% of G. frondosa, initial fasting blood glucose value (170 士 23 mg/dL) 
and maximum blood glucose level (250 士 41 mg/dL) in the glucose tolerance test 
were lower than that of diabetic rats fed with control diet, (225 士 49 mg/dL and 
419 士 55 mg/dL, respectively). In response to glucose loading, the group fed with 
G. frondosa also had higher amount insulin secretion than the control group. 
Although the above experiments only revealed the antidiabetic effect of either the 
hot water extract or fruiting body of G frondosa, it is highly probable that 
polysaccharides are the active hypoglycemic biomolecules as most of the 
antidiabetic water extracts contained hypoglycemic mushrooms polysaccharides 
from previous studies. 
The above fungal polysaccharides or mushrooms have been studied extensively 
for their hypoglycemic actions. Other mushrooms or polysaccharides isolated 
from them have also been evaluated for treating diabetes. For instance, 
exo-polymer from the mycelial culture of Lentinus edodes showed significant 
hypoglycemic effect (Yang et al., 2002), and polysaccharides isolated from 
cultured mycelium of Cordyceps sinensis by hot water also lowered the plasma 
glucose level in diabetic mice (Kiho et al., 1993; Kiho et al., 1996; Kiho et al., 
1999). 
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In the mushroom kingdom, there are still numerous mushrooms which have not 
been thoroughly studied for their high blood glucose ameliorating effects or some 
of which had not been investigated thoroughly. Hericium erinacues is one of the 
examples of the latter. 
1.7 Medicinal Uses of Hericium erinaceus 
K erinaceus, which belongs to Basidiomycetes (Aphyllophoromycetideae, 
Hydnaceae), is known as monkey head mushroom in China or Yamabushitake in 
Japan. According to traditional Chinese medicine, H. erinaceus is good for 
internal organ system and can promote digestion, general vigor, strength and 
nutrition. It may be used for curing neurasthenia and general debility. As shown 
in table 1.6, the main components found in the fruiting body of H. erinaceus 
were carbohydrate, fiber and crude protein (Mizuno, 1999). 
1.7.1 HeLa Cell Proliferation Inhibitors 
Ergosterol (provitamin D) isolated from Coriolus versicolor had a cytotoxic 
effect on hepatoma cells, and other ergosterol derivatives from other mushrooms 
also had cytotoxic effect on cervical carcinoma HeLa cells. 
The ethanol or acetone extracts from H. erinaceus contain three highly active 
substances: Y-A-2(acidic), hercenon A, and hercenon B (neutral). Their structural 
features are shown in figure 1.6. They significantly inhibited the proliferation of 
HeLa cells. The acidic Y-A-2 could also significantly suppress the growth of tea 
pollen tube at concentrations as low as 125 ppm (Mizuno, 1995a). 
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Table 1.6 Chemical Components of Fruiting Bodies of H. erinaceus (% of 
dry matter) 
China Japan 
Crude ash 8.87 9.01 
Crude protein 29.30 27.67 
Crude fat 4.68 4.56 
Crude fiber 7.13 — 
Dietary fiber — 40.15 
Carbohydrate 50.02 18.66 
Calorie/lOOg 355 Cal 227 Cal 
Iron 18 17.5 
Calcium 2 2.9 
Sodium — 2.1 
Potassium --- 4370 
Magnesium … 117.2 
Zinc — 8.0 
B2 1.89 3.14 
B6 - 0.41 
B,2 — 0.15 
A 0.01 — 
Niacin — 16.17 
Ergosteroi — 451.4 




Y-A-2 (Novel oxykeio acid) 
H 一 "eA H ^ C O ^ - ^ ^ ^ 
嶋 双 ⑶ 
Hericenone B 
Figure 1.6 HeLa cell proliferation inhibitors from H. erinaceus (adapted 
from Mizuno, 1999) 
O OH O (IV) Hericenone C 
o ( V ) Hericenone D 
O (VI) Hericenone E 
0 I VII) Hericenone F 
Figure 1.7 NGF synthesis induction promoters from H. erinaceus (adapted 
from Mizuno, 1999) 
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1.7.2 Induction of Growth of Nerve Cells 
Four substances isolated with chloroform from H. erinaceus were reported to 
promote the induction of synthesis of nerve growth factor (NGF). They are 
hericenone C, D, E and F (Y-A-8-c)，with their structural formula being shown in 
figure 1.7. These four substances provided new insight into the treatment of 
Alzheimer's disease (Mizuno, 1999). 
Park and colleagues (2002) reported that the exo-polysaccharide from the culture 
broth of H. erinaceus enhanced the growth of rat adrenal nerve cells. The 
polymer also improved the extension of the neuritis of PC 12 cells, with efficacy 
higher than known nevre growth factors such as NGF and Brain-Derived Nerve 
Factor (BDNF). 
1.7.3 Antitumour Activity 
A hot water extract from H. erinaceus inhibited the growth of intramuscularly 
transplanted Sarcoma 180 ascitic cells. Oral administration of the hot water 
extract at dosages of 250 and 500 mg/kg also caused the tumour regression of 
47.2% and 51.8% of the control, respectively. Intraperitoneal injection of the 
extract inhibited the tumour growth by 55.8% at 50 mg/kg and by 63.0% at 100 
mg/kg (Itoh et al., 1999). According to Mizuno et al. (1992), antitumour active 
polysaccharides isolated from H. erinaceus contain a total of six polysaccharides 
that are effective in inhibiting the growth of Sarcoma 180 cells. 
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1.7.4 Antidiabetic Effect 
The antidiabetic effect of H. erinaceus had once been studied in China by Xue 
and colleagues in 1989. They reported that the polysaccharides from H. 
erinaceus lowered blood glucose level significantly to 49.6% in normal mice 7 h 
after administration at a dosage of 25 mg/kg. In type I diabetic mice induced by 
alloxan, the hypoglycemic effect of this mushroom polysaccharides at dosages of 
6 and 25 mg/kg was the most significant 24 h after administration. Table 1.7 
tabulates the hypoglycemic results of H. erinaceus polysaccharides in normal 
and diabetic mice. 
No information on the extraction of polysaccharides from H. erinaceus was 
provided in the above study. In addition, the statistical methods used to calculate 
blood-glucose lowering effect were different from common methods employed in 
antidiabetic animal studies. Xue and colleagues did not normalize the blood 
glucose level at 0 h to 100% and calculate the subsequent blood level with 
reference to that at 0 h. Therefore, the only information available was that 
polysaccharides isolated from the fruiting body of H. erinaceus seemed to have 
hypoglycemic activity, but their detailed actions were missing or largely 
unknown. Hence, the present research targets at antidiabetic study of H. 
erinaceus in a more systematic and detailed manner. If H. erinaceus does possess 
blood glucose lowering activity , it is worthy to extensively investigate the active 
antidiabetic components and their hypoglycemic mechanisms. As H. erinaceus 





















































































































































































































































































































antidiabetic experiments can encourage the general public to consume it as a 
preventive measure against diabetes. 
1.8 Objectives 
The objectives of this research were as follow: 
I. To extract and characterize polysaccharides with hot water from the fruiting 
bodies of H. erinaceus 
II. To evaluate the antidiabetic potency of the extracted polysaccharides by in 
vitro and in vivo methods. A streptozotocin-induced diabetic murine model 
for the in vivo study of antidiabetic activities and a mechanistic study of the 
hypoglycemic effect of the mushroom polysaccharides were included 
III. To correlate the physico-chemical characteristics of the mushroom 
polysaccharides including sugar and protein content, monosaccharide 
composition, molecular weight and sugar linkage with their antidiabetic 
activities. Hence, the structure and activity relationship (SAR) of H. 
erinaceus polysaccharides will be studied and compared with other 
antidiabetic fungal polysaccharides. 
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Chapter 2 Materials and Methods 
2.1 Extraction of Polysaccharides from the Fruiting Body ofK erinaceus 
2.1.1 Small-scale Extraction 
The fruiting bodies of H. erinaceus (figure 2.1) were supplied by the Sanming 
Mycological Institute in the Fujian Province of Mainland China. The fruiting bodies 
were milled into powder by a hammer mill with a 0.5 mm mesh screen. Due to a 
large amount of small molecular weight substances present in H. erinaceus, the 
mushroom powder was treated with 85% ethanol in a weight/volume ratio of 1 g : 20 
ml ethanolic mixture (figure 2.2). The solution was stirred and heated to 60°C for 2 
h. After ethanol removal of small molecular weight substances by ethanol, the 
residue was filtered and lyophilized. 
About 25 g of dry and ethanol-treated H. erinaceus powder was mixed with 500 ml 
distilled water, and the mixture was boiled for 2 h. The hot water extract was 
centrifuged at 10,000 rpm at 25�C for 45 min and the supernatant collected was 
further filtered by a cheese cloth to remove suspending particulates. The insoluble 
mushroom powder remained was subjected to the same hot water extraction twice. 
Three portions of hot-water extracts were pooled together and then poured into a 
dialysis tube with a molecular weight cut off (MWCO) of 6,000-8,000. The extract 
was dialyzed against distilled water and then ultrapure water until the total dissolved 
solute (TDS) of the dialysate was lower than Img/L. The extract was then 
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lyophilized to give a crude fraction. 
The crude fraction was dissolved in a minimum amount of water and subjected to 
Sevag treatment (Staub, 1965) to remove protein. In brief, one volume of aqueous 
solution of reconstituted hot water extract was mixed with 3 volume of chloroform in 
a separating funnel. The funnel was inverted several times to enhance the mixing of 
reconstituted hot water extract with chloroform. The organic layer containing 
denatured protein was discarded. The Sevag process was repeated until no more 
soluble protein could be removed from the aqueous fraction. The deproteinized hot 
water extract of H. erinaceus was then freeze-dried to give a polysaccharide fraction 
termed as HE-DP (figure 2.2). 
2.1.2 Large-scale Extraction 
The conditions of the large-scale extraction were based on the small-scale one with 
several modifications to facilitate the sample handling (figure 2.3). 
The fruiting bodies of H. erinaceus (figure 2.1) were supplied from a purchasing 
agent in Hong Kong, which had supply of H. erinaceus in Mainland China. The 
whole mushrooms were first disintegrated into smaller portions manually and then 
lyophilized. The dried H. erinaceus was then milled into powder by a hammer mill 
with a 1 mm mesh screen. For removal of small molecular weight substances, 95% 
ethanol instead of 85% ethanol was used and the weight to volume ratio was changed 
from 1 : 20 g/ml to 1 g to 7 ml of ethanol. The ethanol treatment was conducted at 
room temperature instead of 60°C with continuous stirring for 12 h. After filtering 
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through cheese cloth, the insoluble mushroom residue was subjected to a second 
ethanol treatment. The filtered residue would then be washed by acetone and then 
oven-dried. 
About 1.6 kg of ethanol-treated H. erinaceus powder was mixed with 24 L of tap 
water to extract mushroom polysaccharides by boiling the mixture for 2 h with 
occasional manual stirring. After the extraction, the hot mixture was then kept at 
room temperature for cooling and sedimentation of residue. The extract was then 
separated from the residue by a centrifuge (model: s212, Tan Far Company). The 
extraction was conducted for 2 times. 
All the extracts were pooled and refrigerated at 4�C overnight to separate the cold 
water-soluble and cold water-insoluble fraction. A gel-like cold water-insoluble 
fraction was formed during refrigeration, and it was collected as a pellet after 
centrifugation at 10000 rpm at 4�C for 20 min and then lyophilized. The cold 
water-soluble fraction was collected as supernatant, concentrated by ultrafiltration 
(see below) and then lyophilized. 
The ultrafiltration system (Pall Gelman Maximate System) was equipped with a 
membrane cassette with a MWCO of 10,000. The retentate collected from the cold 
water-soluble fraction as a concentrate was kept while the filtrate was discarded. At 
the same time, any impurity from tap water was removed during ultrafiltration. The 
total dissolved solute (TDS) of the retentate was monitored during ultrafiltration. 
After successive ultrafiltration, the process was completed when the TDS reading 
was lower than 10 mg/L. All the retentates were then dialyzed against distilled water 
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with a MWCO of 6,000-8,000. After the TDS reading of the dialysate had been 
lowered to 1 mg/L, part of this large-scale hot water extract was lyophilized to give a 
fraction known as HE-CS; and part of this extract was further deproteinized by the 
Sevag treatment mentioned in the small-scale extraction (2.1.1). The deproteinized 
large-scale hot water extract of H. erinaceus after drying was termed HE-CSD. 
The lyophilized cold-water-insoluble fraction (50g) was redissolved in boiling water 
in a ratio of 1 g : 25 ml with continuous stirring for 2 h. The extract was collected as 
supernatant after centrifligation at 10000 rpm at room temperature for 45 min, and 
then was dialyzed against distilled water with a MWCO of 6,000-8,000. The extract 




Figure 2.1 The fruiting bodies ofH. erinaceus 
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H. erinaceus powder 
- e x t r a c t e d with 85% ethanol 
- w : V = 1 g : 20 ml 
- 6 0 � C , 2-hour stirring, repeated 2 times 
- c e n t r i f u g e d & filtered 
Desugared H, erinaceus powder (25g) 
- e x t r a c t e d with distilled water 
- w : V = 1 g : 20 ml 
- 1 0 0 ° C , 2-hour stirring, 
repeated 3 times 
- c e n t r i f u g e d & filtered 
I lyophilized 
Supernatant ，， 




Hot-Water-Soluble and Deproteinized 
Polysaccharide (HE-DP) 
Figure 2.2 Small-scale extraction of polysaccharide from the fruiting bodies of H, erinaceus 
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H. erinaceus powder 
- extracted with 95% ethanol 
- w: V = 1 g : 7 ml 
- room temp., 12-hour stirring, repeated 2 tomes, 
filtered by cheesecloth 
- acetone washing 
- oven drying 
Desugared H. erinaceus powder (1.6kg) 
- extracted with tap water 
- w: V = 1 g : 1.5 ml 
- 100°C, 2-hour stirring, repeated 2 times 
- cooling and sedimentation at room temp. 
- separation by centrifugation 
Hot water extract 
storage at 4°C overnight & centrifuged 
I  
” ” 
Supernatant: cold water soluble fraction cold water insoluble fraction^ 
ultrafiltration Extraction of HE-Cl" 
- redissolved in distilled water 
” w: V = 1 g : 25 ml 




^ i i Sevag lyophilized Pellet: residue Supernatant deproteinization Cold-Water-Soluble & lyophilized dialyzed & lyophilized Non-deproteinized Polysaccharide Cold-Water-Soluble & (HE-CS) Cold-Water-Insoluble Deproteinized Polysaccharide (HE-CI) 
Polysaccharide 
(HE-CSD) 
Figure 2.3 Large-scale extraction of polysaccharides from the fruiting bodies of H. erinaceus 
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2.2 Physico-Chemical Characterization of HE-polysaccharides 
2.2.1 Carbohydrate Content: Phenol-Sulfuric Acid Method 
This method was modified from the one described by Dubois et al. (1956). Fifteen 
milligrams of HE-DP, HE-CSD, HE-CS, and HE-CI were dissolved in 5 ml distilled 
water as stock solutions and diluted appropriately. Diluted sample solutions (0.5 ml) 
were vortex-mixed with 0.5 ml of 5% phenol in water. After mixing, a further 2.5 ml 
18M sulfuric acid was added to each tube and followed by immediate mixing. A 
30-minute incubation period was required for the reaction to proceed. The 
absorbance of each sample was then measured with spectrophotometer at a 
wavelength of 490 nm. A calibration curve was constructed with glucose standards 
ranged from 0 to lOOjig/ml, by following the same procedure. The total carbohydrate 
content of each sample was determined from the calibration curve and multiplied by 
the dilution factor in the above procedure. The total sugar content was shown in 
percentage which was calculated by the formula below: 
Total Carbohydrate Content (%) 
= [conc. determined from standard curve (jiig/ml) x dilution factor X vol. of the 
sample (5 ml) x 100 %] / [sample weight x 1000 (|Lig)] 
2.2.2 Protein Content: Lowry Assay 
The protein content of the samples was measured by a protein assay kit of Sigma 
Diagnostics Company (Bensadoun and Weinstein, 1976; Peterson, 1977). Fifteen 
milligrams of HE-DP, HE-CSD, HE-CS, and HE-CI were dissolved in 5 ml distilled 
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water, followed by a 1/10 dilution. The protein standard in the assay kit was 
reconstituted with distilled water to give a 400 ^g/ml protein stock solution. A series 
of protein standards with different concentrations (50-400|ig/ml) was prepared from 
the protein stock solution. Distilled water was used as blank in this assay. One 
milliliter of Lowry reagent was added to samples, standards and blank. After mixing, 
all tubes were left at room temperature for 20 min. Then 0.5 ml of Folin & 
Ciocalteu's phenol solution was added to each tube, accompanied with rapid and 
immediate mixing after addition. The tubes were left for 30 min for colour 
development. The absorbance of the blank, standards and samples were measured 
with a spectrophotometer at a wavelength of 750 nm within 30 min. The protein 
concentration of the samples was calculated with the standard curve constructed and 
corrected with the dilution factors to obtain the protein level in the original sample. 
The protein value was calculated by the following formula expressed in percentage. 
Protein Level (%) 
= [conc. determined from standard curve (|Lig/ml) x dilution factor x vol. of the 
sample (5 ml) X 100 %] / [sample weight x 1000 (fig)] 
2.2.3 Uronic Acid Content 
The uronic acid content measurement was adopted from the Official Method of 
Analysis 45.4.11 (AOAC, 1995; Theander et al., 1995). Part of the HE-DP, HE-CSD, 
HE-CS and HE-CI acid hydrolyzed samples obtained in neutral sugar analysis by gas 
chromatography, described in section 2.6.1，was retained for the measurement of the 
uronic acid content. 
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An aliquot of 0.15 ml acid hydrolysate was diluted with 0.15 ml of 2M sulfuric acid 
to make up a volume of 0.3 ml; the mixture was added to 0.3 ml sodium 
chloride/boric acid solution, composing of 2 g sodium chloride and 3 g boric acid in 
100 ml distilled water. After mixing, 5 ml of 18M sulfuric acid was added to the 
above mixture with vortex-mixing, followed by a 40-min incubating period at 70°C. 
Subsequently, the mixtures were cooled to room temperature and 0.2 ml 
dimethylphenol, prepared by dissolving 0.1 g 3,5-dimethylphenol in 100 ml glacial 
acetic acid, was added. After mixing, all the tubes were kept at room temperature for 
a further 10 min. The absorbance was measured with a spectrophotometer at 400 nm 
and 450 nm against the blank; the absorbance at 400 nm was subtracted from 450 nm 
to correct for interference from hexoses. 
Glucuronic acid standards of 10, 100, 200 and 500|ig/ml were prepared with the 
same procedure while 2 M sulfuric acid was used as the blank. The uronic acid 
contents of HE-DP, HE-CSD, HE-CS and HE-CI were calculated from the 
glucuronic acid standard curve and corrected by the dilution factor. Uronic acid 
contents in HE-DP, HE-CSD, HE-CS and HE-CI were calculated as: 
Uronic Acid Content (%): 
= [conc. determined from the standard curve (|ag/ml) X dilution factor X vol. in 
acid depolymerization (4.2 ml) X 100%] / [sample weight x 1000 (jug)] 
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2.2.4 Molecular Weight Determination by High Pressure Liquid 
Chromatography (HPLC) 
The molecular weights of HE-CSD, HE-CS. and HE-CI were determined by 
size-exclusion chromatography. Polysaccharide, pullulan (Shodex)，with molecular 
weight of 0.59 x 10^ (P-5), 1.18 x 10^ (P-10), 2.28 x 10^ (P-20), 4.73 x 10^ (P-50), 
11.2 X 104 (P-100), 21.2 X 104 (P-200), 40.4 x 10-^(P-400), 78.8 x lO'^ CP-SOO) and the 
samples were dissolved in 0.2 M NaCl, which had been degassed before use. The 
pullulan standard and the sample solutions were filtered with membrane of 0.45 }im 
before injection into the HPLC system. The HPLC system (Hewlett Packard Series 
1000) was equipped with a Progel™-TSK G6000 PW column (30 cm length x 7.5 
mm i.d., Superlco, U.S.A.), and a PWH guard column (7.5 cm length x 7.5 mm i.d., 
Superlco, U.S.A). The eluent was 0.2 M NaCl and the flow rate was adjusted to 1 
ml/min at 25°C. The signal of the polysaccharides was detected by a refractive index 
detector (WATERS 410). The approximate molecular weights of the samples were 
determined by comparing the elution profile of the samples to that of the pullulan 
standards. 
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2.2.5 Determination of Monosaccharide Composition of Non-Starch 
Polysaccharides by Gas Chromatography (GC) 
The purified polysaccharides were subjected to sequential acid hydrolysis into 
monosaccharides and then derivatized as alditol acetates according to Englyst's 
procedure (Blakeney et al., 1983) 
2.2.5.1 Acid Depolymerisation 
About 8 mg sample was hydrolyzed with 0.7 ml of 12 M sulfuric acid at 35°C for 60 
min with continuous stirring. The mixture was diluted to 2 M sulfuric acid by the 
addition of 3.5 ml distilled water, and the mixture was vortex-mixed and heated in a 
boiling water bath for 60 min, followed by cooling to room temperature. 
2.2.5.2 Neutral Sugar Derivatisation 
Three milliliters of hydrolysate was transferred to a test-tube and 1 ml of internal 
standard (allose, 1 mg/ml) was added. Following adjustment of pH of the hydrolysate 
to alkaline by the addition of sufficient amount of 12 M ammonia, 5 jiil octan-l-ol 
and 0.2 ml of freshly prepared sodium borohydride (200 mg/ml 2M ammonia) were 
added to reduce the monosaccharides. The mixture was kept at 40�C for 30 min and 
0.4 ml of glacial acetic acid was then added and vortex-mixed. An aliquot (0.2 ml) of 
the sample mixture was then transferred to a new test-tube with the addition of 2.0 
ml acetic anhydride to acetylate the mixture. 1-Methylimidazole (0.3 ml) was added 
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as a catalyst and the mixture was kept at room temperature for 10 min after 
vortex-mixing. Five milliliters of distilled water was added, and the mixture was 
vortex-mixed and cooled to room temperature. Dichloromethane (1 ml) was added 
and the mixture was vortex-mixed and stood for 10 min for phase separation. The 
upper aqueous phase was removed, and the lower organic phase was washed twice 
with 1 ml of distilled water. The lower phase was dried with anhydrous sodium 
sulfate and then stored in a vial at -20°C before gas chromatography (GC) analysis. 
2.2.5.3 Determination of Neutral Sugar Composition by Gas Chromatography 
(GC) 
The alditol acetates derivatives of the neutral sugars were quantified by gas 
chromatograph (Hewlett-Packard 6890, USA) using an Alltech DB-225 capillary 
column (15 m X 0.25 mm i.d.，0.25 jim film). An oven temperature program of initial 
temperature of 180�C，followed by a programmed increase of 2°C/min to 220�C and 
a final hold of 25 min. The injector and heater temperature was 220�C. The carrier 
gas was helium and detection was by flame ionization. Individual sugars were 
corrected for losses during hydrolysis and derivatisation, and for the response to the 
flame ionization detector. Monosaccharide standards used for calibration included 
fucose，ribose, arabinose, xylose, mannose, galactose, glucose, glucosamine and 
galactosamine. N-Acetylglucosamine was detected as glucosamine because the 
N-acetyl group at C-2 would be deacetylated by the sulfuric acid hydrolysis. The 
values for monosaccharides were expressed as polysaccharide residue 
(anhydro-sugar) by multiplying the amounts of pentoses and methyl pentoses with a 
factor of 0.88 and 0.89 respectively, and of hexoses with a factor of 0.9. 
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The conversion of peaks in the GC profiles into corresponding monosaccharide 
composition of each sample was calculated by the formulas below. 
Response factor (Rf) 
=[monosaccharide conc. in standard (mg/mO x 1.5 ml x area of allose in 
standard] 
Area of monosaccharide in standard x 1 mg/ml x 1 ml 
X = Rf (average from 2 repeats) x coefficient of individual sugar 
Table 2.1 Coefficient of Individual hexose 
1.232 (=4.2 ml X 0.88/3ml) 1.246 (=4.2 ml x 0.89/3ml) 1.26 (= 4.2 ml x 0.9/3ml) 
Ribose Rhamnose Mannose 
Arabinose Fucose Galactose 
Xylose Allose Glucose 
Glucosamine 
Galactosamine 
Y = area of monosaccharide in sample x 1 mg/ml x 1 ml (mg) 
Area of allose in sample 
Monosaccharide (%) 
=X X Y(mg) X 100 / sample weight (mg) of GC 
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2.2.6 Structural Study of Polysaccharides by Methylation 
2.2.6.1 Preparation of dry Dimethyl Sulfoxide (DMSO) 
The methylation procedure was based on the method described by Mukerjea et al. 
(1996). Five hundred milliliters of reagent-grade DMSO was stirred with excess 
calcium hydride (CaH) in a three-necked round bottom flask at 65°C for 3 h. Then 
the DMSO was distilled under nitrogen at reduced pressure for 5 h. After distillation, 
the dry DMSO was transferred with a glass syringe into a 500-ml round bottom flask, 
which was previously flushed with nitrogen and filled with pre-dried molecular sieve. 
The flask was sealed tightly with a rubber cap and covered with aluminum foil to 
avoid the exposure to light, and finally was stored at 4°C. 
2.2.6.2 Preparation of Methylsulfinyl Methyl Sodium (CH3SOCH2 Na+) from the 
dry DMSO and Sodium Hydride 
Two grams of sodium hydride was added into a 50-m centrifuge tube and hexane was 
filled up to a total volume of 30 ml. After centrifugation at 3000 rpm for 5 min, 
hexane was discarded. This hexane washing process was repeated to remove the oil 
on the surface of sodium hydride. Sodium hydride was consequently collected as a 
pellet in the centrifuge tube and transferred into a dried 3-necked flask previously 
flushed with nitrogen with a minimum amount of hexane. The 3-necked flask was 
flushed with argon to evaporate the remaining hexane. When the sodium hydride was 
dry, 30 ml of dry DMSO was added by a glass syringe into the 3-necked flask. The 
flask was kept at room temperature for 30 min and the mixture was sonicated at 25�C 
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for 1 h until the colour changed to greylish green. After sonication，the 
methylsulfinyl methyl sodium was stored in several 5-ml serum bottles, pre-flushed 
with nitrogen, and sealed by cap with septum. Methylsulfinyl methyl sodium was 
stored away from light at -20°C. For methylation, methylsulfinyl methyl sodium was 
thawed and removed through the septum of the cap with the use of a glass syringe. 
2.2.6.3 Methylation Procedure 
About 4 mg of HE-CS and HE-CI was weighed into a capped serum bottle and was 
dried with phosphorus pentoxide overnight in vacuum. After drying, 1 ml dry DMSO 
was added to the bottles with a glass syringe under argon. The mixture was 
vortex-mixed and sonicated at room temperature for 30-50 minutes. 
When the samples were solubilized in DMSO, then 0.4 ml methylsulfinyl methyl 
sodium was added and the mixture was vortex-mixed. The gel formed after mixing 
was broken up by sonication at 25�C for 60-90 minutes. Followed by the addition of 
0.3 ml chilled methyl iodide, the mixture was sonicated at 25°C for 15-20 min, and 
was kept at room temperature for 2 hours. 
If the samples were insoluble in DMSO, premethylation was conducted to enhance 
solubility. Methylsulfinyl methyl sodium (20^1) was added and the mixture was kept 
in an ice bath until frozen; and a further 5 fxl methyl iodide was added. The above 2 
steps were repeated but with 60 |li1 methylsulfinyl methyl sodium and 15 )li1 methyl 
iodide. After premethylation, the samples were processed in the same way as the 
DMSO-soluble samples. 
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After 2 h incubation, 0.3 ml distilled water was added to neutralize excess 
methylsulfinyl methyl sodium and the resulting suspension was transferred into a 
15-ml centrifuge tube. The methylated polysaccharides were extracted from the 
suspension with an addition of 4 ml chloroform, and were then washed by 3 ml 
distilled water. The mixture was centrifuged at 3000 rpm for 5 min and the top water 
layer was discarded after phase separation. This washing process was repeated 3 
times. After the last wash, the remaining water in the tube was dried by adding 3 ml 
2,2-dimethoxypropane and 40 |al glacial acetic acid. The solvent in the end product 
was removed by evaporation at 40�C under nitrogen to give a dry product. 
2.2.6.4 Preparation of Partially Methylated Alditol Acetates (PMAAs) 
The methylated polysaccharide was hydrolyzed with 0.6 ml of 2M trifluoroacetic 
acid in a capped tube previously flushed with nitrogen and was heated at 121 °C for 1 
hours. After the completion of hydrolysis, the tube was cooled to 40°C and the 
hydrolysate was dried with nitrogen. 
Then the hydrolysate of the methylated polysaccharide was reduced and acetylated 
by following the same procedure in the GC analysis, described in section 2.6.2, 
starting from the adjustment of pH by adding 0.5 ml of 12 M ammonia into the 
samples. 
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2.2.6.5 Analysis of the PMAAs by GC 
The partially methylated alditol acetates (PMAAs) samples were analyzed by 
GC-MS (GCMS-QP5050, Shimadzu，Japan). The GC part was equipped with an 
HP-5MS capillary column (5% phenyl methyl siloxane, 30 m x 25 jiim i.d., 
Hewlett-Packard). Helium was the carrier gas and the flow rate was adjusted to 1.2 
ml/min. The initial oven temperature was 130�C, and was increased to 280�C at a 
rate of 3�C/min. The interface temperature was 250°C, and the split ratio was set at 
30:1. 
Regarding the MS conditions, the ion source temperature was 250°C with an 
ionization energy of 70eV; the voltage of detector was 1.5 kV and mass range of 
50-350. The spectra of the PMAAs were compared with that of known standards in 
the GC-MS library . 
2.2.7 The Measurement of Viscosity 
The specific viscosity of HE-CS and HE-CI were measured by a glass capillary 
viscometer (Ever Ready Thermometer Company Inc., cat no.: U-98931-29). HE-CS 
and HE-CI were reconstituted in distilled water to obtain concentrations of 5% and 
0.5 %, respectively. A 1% low viscosity alginic acid (Sigma, a sodium salt from 
Macrocystis pyrifem, viscosity of 2% solution at 25°C being approximately 250 
centipoises) was used as a reference in this measurement. HE-CS, HE-CI and alginic 
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acid were completely vortex-mixed to ensure homogeneity of the whole sample 
before measurement. 
The viscometer used is a cannon-ubbelohde type and its size was number 100 
(viscometer constant at all temperatures: 0.01432 centistokes/second; measured 
viscosity range: 3-15 centistokes). The viscometer was cleaned with chromic acid 
before use to remove any organic matter deposited on the glass wall. The viscometer 
was held firmly in a 50-litre tank filling with water at 24°C，maintained by a 
thermo-circulating bath. The sample was poured into the reservoir of the viscometer 
to about one-half full and kept for 20 min to reach the temperature equilibrium of the 
bath. After equilibration, the sample was sucked into the capillary tube of the 
viscometer with a hand pump to reach its upper mark. The time for a sample solution 
in the capillary tube to pass through between the upper mark and the lower mark was 
measured (in seconds). In order to calculate the kinematic viscosity in centistokes, 
the efflux time in seconds was multiplied by the viscometer constant. In addition, the 
specific viscosity of HE-CS, HE-CI and 1 % of low viscosity alginic acid were also 
determined by dividing the efflux time of the samples with that of distilled water. 
Viscosity (centistokes) = efflux time (seconds) X viscometer constant 
(centistokes/second) 
Specific viscosity r| = Efflux T i m C s a m p i e / Efflux Timedistiiied water 
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2.3 In vitro Hypoglycemic Tests of HE-Polysaccharides 
Two in vitro hypoglycemic tests, based on the methods described by Ou et al. (2001) 
and Chau, Huang and Lee (2003) with slight modifications, were conducted to study 
the possible actions of the HE-CS, HE-CI in lowering blood glucose level. 
2.3.1 Glucose Dialysis Retardation Index (GDRI) 
2.3.1.1 Experimental Setup 
A glucose solution was prepared by adding 18 g of glucose in a 1-litre volumetric 
flask followed by the addition of distilled water to obtain a 100 mmol/L glucose 
solution. HE-CS, HE-CI and low viscosity alginic acid were dissolved separately in 
the 100 mmol/L glucose solution with stirring to give 2% HE-CS, 0.5% HE-CI and 
1% low viscosity alginic acid (as positive control) solutions; while the lOOmM 
glucose solution without addition of any fiber was used as a blank. Aliquots of 25 ml 
of blank, positive control and samples were transferred into dialysis bags with a 
MWCO of 6,000-8,000. The dialysis bags were sealed with clips at both ends and 
submerged in 200 ml ultrapure water at 37°C. Two milliliters of dialysate was taken 
at 10, 20, 30, 60, 90, 120, 150, 180, 300 and 360 min after the dialysis had begun. 
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2.3.1.2 Measurement of Glucose in the Dialysate 
The glucose content of the dialysate was measured using the glucose assay kit from 
Megazyme, based on the principles of glucose oxidase and peroxidase reactions. 
Glucose in the dialysate was oxidized by glucose oxidase and the end product, 
hydrogen peroxidase, reacts with phenol and 4-aminoantipyrine under the effect of 
peroxidase to form a red-violet quinoneimine dye. The amount of glucose in the 
dialysate was proportional to color intensity. 
A mixture of 0.1 ml dialysate and glucose standard (1 mg/ml) were mixed with 0.1 
ml distilled water and a blank was prepared with 0.2 ml distilled water. The samples, 
standard and blank were mixed with 3 ml chromogen reagent composing of glucose 
oxidase, peroxidase and 4-aminoantipyrine, and the mixtures were kept at 40�C for 
20 minutes. The absorbance of the mixture was measured with a spectrophotometer 
at 510 nm against the reagent blank. 
The glucose concentration of the dialysate was calculated by the following formula: 
Glucose Concentration (mg/ml) 
=(absorbance of the sample / absorbance of the glucose standard) x 1 mg/ml 
The Glucose Diffusion Retardation Index (GDRI) at different time periods was 
calculated by the following equation: 
= 1 0 0 - [(glucose content of the sample/glucose content of the control) x 100] 
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2.3.2 Inhibition of Amylolysis 
2.3.2.1 Experimental Setup 
The method to measure the inhibition of a-amylase by HE-polysaccharides was 
based on the one described by Ou et al. (2001) and Chau, Huang and Lee (2003) with 
slight modifications. A 4% dextrin (Sigma) solution was prepared by adding 20 g 
dextrin into a 500 ml-volumetric flask, followed by addition of 0.05 M MES/TRIS 
buffer at pH 8.2 to make up the volume. The 4% dextrin solution was used to 
compose 2% HE-CS, 0.5% HE-CI and 1% low viscosity alginic acid (as a positive 
control); while the dextrin solution was used as a blank. Aliquots of 25 ml of blank, 
positive control, HE-CS and HE-CI solutions were poured into a dialysis bag with a 
MWCO of 6,000-8,000. Then 50 |xl of a-amylase (A-3306, heat-stable from Bacillus 
licheniformis) from the total fiber assay kit (Sigma Diagnostic) was added to the 
solution in the dialysis bag, following by sealing of the dialysis bag at both ends with 
clips. The dialysis bags were inverted several times and dialyzed against 200 ml 
ultrapure water at 37°C. Two milliliters of dialysate was collected at 20, 30, 60，90, 
120, 150 and 180 minutes for the measurement of maltose after the start of the 
experiment. 
2.3.2.2 Measurement of Maltose in the Dialysate 
During digestion, maltose is the main kinetic component from the a-amylase which 
was measured by a colorimetric method. The dialysate (0.5 ml) was mixed with 1 ml 
of 3,5-dinitrosalicyclic acid. The mixtures were kept in a boiling water bath for 10 
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min and followed by cooling to room temperature. After adding 4.75 ml of distilled 
water, the absorbance of the mixture was read at 550 nm. Maltose standards wtih 
concentrations from 0-5 mg/ml were prepared, and maltose contents of the dialysates 
were calculated from the standard curve. 
The inhibition of amylolysis determined as a function of time was calculated by the 
following formula. 
Amylolysis Inhibition 
=100 - [(maltose content of the sample/maltose content of the control) x 100] 
2.4 In vivo Hypoglycemic Evaluation of HE-Polysaccharides 
2.4.1 Oral Glucose Tolerance Test (OGTT) 
The oral glucose tolerance test was based on the one conducted by Kiho and 
colleagues (1997). Eight to nine-week-old female BALB/c mice were supplied from 
the Laboratory Animal Service Center (LASEC) of CUHK to test the blood-glucose 
suppressing effect of the extract when they were fed simultaneously with glucose to 
the mice. 
HE-CS and HE-CI were dissolved in a 100 mg/ml glucose solution to make up to 50 
mg/ml of HE-CS and 15 mg/ml of HE-CI solutions. The doses used to feed the mice 
were 0.5 g/kg body wt. and 0.15 g/kg body wt for HE-CS and HE-CI, respectively. 
The amount of glucose fed to the mice, simultaneously with the extract, was 1 g/kg 
body wt. and the control group was fed with 100 mg/ml glucose solution only. The 
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feeding volume (ml) was equal to the body weight in gram divided by 100. For 
instance, in order to feed a dose of 0.5 g HE-CS per kilogram body weight into a 25 
g BALB/c mouse, the volume fed to the mouse was 0.25 ml. [(50 x 0.25) HE-CS mg 
/ (25 kg/ 1000)] 
The mice were kept in cages for 3 days for adaptation. Before the test, the mice were 
to fast overnight. After oral feeding of the samples, blood was collected from the 
orbital sinus of the mice at 0，0.5, 1，2 and 3 h after feeding. During the test, the mice 
were strictly deprived of any diet. The blood glucose level of the plasma at the above 
time intervals was measured by the enzymatic blood glucose assay kit (Stanbio 
Laboratory). 
The experiments were repeated with increased dosage of HE-CS from 0.5 to 1.5 g/kg， 
and HE-CI from to 0.15 to 0.4g/kg. At the same time, the effect of HE-CS on male 
BALB/c mice of the same age was also investigated with a feeding dosage of 1 g/kg 
with other parameters remained unchanged. 
The plasma blood glucose level at 0 hour was normalized to 100% while the glucose 
level at the other time periods was calculated as a relative percentage with reference 
to that of 0 hour according to the formula: 
Relative Glucose Level (%) 
=[glucose level at other time period (mg/dL) / glucose level at 0 hr (mg/dL)] X 100% 
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2.4.2 Induction of Type I Diabetes in Normal BALB/c Mice 
2.4.2.1 Induction Protocol 
Adult 8-9 week-old male BALB/c mice were supplied from the Laboratory Animal 
Service Center (LASEC) of the Chinese University of Hong Kong. On the day of 
arrival (Day -3), six mice were housed in a cage with sawdust bedding and free 
access to water and diet for 3 days’ acclimation. The mice were fasted for 12 h before 
injection of streptozotocin (Day -1), in figure 2.4. On the day of injection of 
streptozotocin (STZ) (Day 0), blood was withdrawn from the orbital sinus of the 
mice with a heparinized capillary tube. The blood was kept in an ice bath for 
temporary storage. 
The diabetes induction procedure was adapted from Kurup and Bhonde (2000) with 
modifications. The streptozotocin (Wako) was reconstituted in chilled 50 mM 
sodium citrate buffer with a pH of 4.5 to give an 18 mg/ml pale yellow solution. The 
injection volume (ml) was equal to the body weight of the mice in gram divided by 
100, and thus the dosage of STZ injected was 180 mg/kg. For instance, the injection 
volume of STZ solution (18 mg/ml) into a 25 g BALB/c mouse was 0.25 ml. Then 
the dosage was 180 mg of STZ per kilogram of the BALB/c mouse [= (18 x 0.25) mg 
/ (25/ 1000) kg]. 
The intraperitoneal pathway was the route of administration and 78% ethanol was 
used to sterilize the region of injection. It was crucial that STZ was prepared just 
before injection and used within 2 min after reconstitution. The blood collected was 
centrifuged at 3000 rpm at 4°C for 10 min to collect the plasma, which was subject 
69 
to glucose measurement. 
The fasting plasma glucose level of the normal BALB/c mice before injection of STZ 
(Day 0) was checked. On day 5, the fasting plasma glucose level of the mice after the 
injection of streptozotocin was evaluated again. When the fasting blood glucose level 
was over 200 mg/dL，the mice were considered diabetic and could be used for 
subsequent test on day 7. Figure 2.4 shows the sequence of events in the induction of 
type I diabetes in normal BALB/c mice 
• • • • • • 
Day -3 -2 -1 0 1 2 3 4 5 6 7 8 
Day Events 
-3 Arrival of 8-9-week-old male BALB/c mice 
-1 Overnight fasting 
0 i) Blood collection; ii) Injection of STZ; iii) Measurement of fasting plasma glucose level 
4 Overnight fasting 
5 i) Blood collection; ii) Measurement of fasting plasma glucose level; iii) Checking diabetes 
status 
7 Hypoglycemic test 
Figure 2.4 Time line of events for the induction of type I diabetes in normal 
BALB/c mice 
2.4.2.2 Measurement of Plasma Glucose Level 
Glucose level in the plasma was measured using an enzymatic assay kit (Stanbio 
Laboratory), based on the same principle of the glucose assay kit from Megazyme. 
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Ten microliters of plasma and glucose standard were mixed with 1 ml reacting 
reagent that contained 4-aminoantipyrine, glucose oxidase, peroxidase and phenol; 
the sole reacting agent was treated as blank. After vortex-mixing, all the plasma 
sample, standard and blank were kept at room temperature for 10 min. The 
absorbance was measured with a spectrophotometer at 500 nm. Glucose 
concentration of the plasma was calculated by the following equation: 
Glucose Concentration (mg/dL) 
=(absorbance of sample / absorbance of standard) x 100 (mg/dL) 
2.4.3 Hypoglycemic Test on Normal and Diabetic BALB/c Mice 
The hypoglycemic test was adapted from Kiho and colleagues (1995). Type I 
diabetic mice prepared from the above induction procedure in 2.4.2.1 and normal 
8-9-week-old male BALB/c mice supplied from the LASEC were used to study the 
hypoglycemic effect of the extracts. 
In this test, fasting was not required. HE-CSD, HE-CS and HE-CI were dissolved in 
physiological phosphate saline of pH 7.4 and injected at various dosages (100 -200 
mg/kg body weight) into the intraperitoneal cavity of diabetic and normal mice. 
Blood was collected from the orbital sinus of the mice with heparinized capillary 
tube at 0，3, 6 and 24 h after injection of the samples. During the test, the mice had 
free access to water and the diet. Plasma was collected after centrifugation of the 
blood samples at 3000 rpm at 4°C for 10 min and glucose level was measured using 
the enzymatic glucose assay kit (Stanbio Laboratory). A control group was prepared 
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by the injection of physiological saline. 
The plasma glucose values were normalized to 100% at 0 h and the glucose level at 3, 
6 and 24 h were calculated as a relative percentage with reference to that of 0 h by 
the following formula. 
Relative Glucose Level (%) 
二 [glucose level at 3/6/24 hrs (mg/dL) / glucose level at 0 hr (mg/dL)] x 100% 
2.4.4 Measurement of Insulin Level by Enzyme-Linked Immunoadsorbent 
Assay (ELISA) 
2.4.4.1 Plasma Samples used in ELISA 
After glucose measurement in the hypoglycemic test (2.12), the plasma samples 
remains were used to measure the change of insulin level by an ELISA kit (Crystal 
Chem INC) (Butler, 1994; Engvall and Perlmann, 1972; Ngo, 1985). 
In the hypoglycemic tests of normal and diabetic mice, plasma from the groups of 
mice injected with 200mg/kg of HE-CS, lOOmg/kg of HE-CI and control group (6 
groups in total) were chosen. Two plasma samples were selected as representative 
from each group. The insulin level of the plasma of the normal mice was monitored 
at 0, 3, 6 and 24 h while for that of the diabetic mice, only the 0, 3 and 24 h insulin 
levels were accessed. 
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2.4.4.2 Assay Procedure 
First Reaction: binding of the mice insulin to the Guinea pig anti-rat insulin 
antibody coated on the microplate well. 
The chilled antibody coated 96-well microplate was equilibrated to room temperature 
and the plate was fixed to a frame. Ninety-five microliters of sample diluent was 
added to each well, followed by the addition of 5 |j1 of plasma and mice insulin 
standard (0, 0.2, 0.4, 0.8, 1.6，3.2 ng/ml). Then the microplate was covered and 
incubated at 4°C for 2 h. 
Second Reaction: binding of horseradish peroxidase (POD)-conjugated anti-rat 
insulin antibody to the Guinea pig anti-rat insulin antibody/mice insulin of the 
complex immobilized on the wall. 
After the incubation period, the well content was aspirated and the microplate was 
washed with 300 |il washing buffer for 5 times. After the last wash, the remaining 
solution on the plate was removed by inverting the plate on a clean paper towel. Then 
100 |il rat insulin enzyme conjugate was dispensed to each well. The binding reaction 
was allowed to proceed at room temperature for 30 min. 
Enzyme Reaction: detection of bound POD conjugate on the microplate well by 
the 3,3', 5, 5'-tetramethylbenzidine (TMB) substrate solution 
The well content was discarded and the plate was washed with 300 )il washing buffer 
for 7 times. After the last wash, the solution left on the plate was removed by 
inverting the plate on a clean paper towel. Immediately after washing, 100 \x\ enzyme 
substrate solution was added to each well and the reaction proceeded at room 
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temperature for 40 minutes. The plate was kept away from light during the 
incubation period. This enzymatic reaction was terminated by adding 100 jiil enzyme 
reaction stopping solution. The absorbance of the plate was measured at 450 nm and 
630 nm within 30 minutes. The reading at 630 nm was subtracted from that of 450 
nm. The mice insulin concentration (ng/ml) was calculated from the standard curve. 
2.5 Statistical Evaluation 
The results from the in vitro hypoglycemic test, OGTT, hypoglycemic test on normal 
and diabetic mice, as well as ELISA (2.9 — 2.13) assays were analyzed by student 
Mest. Differences were considered significant when p value < 0.05. In the 
hypoglycemic test on normal mice, one-way analysis of variance (ANOVA) was also 
conducted. 
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Chapter 3 Results and Discussion 
3.1 Yield of Polysaccharides extracted from H. erinaceus 
Table 3.1 shows the yield of extraction of polysaccharides from desugared H. 
erinaceus powder in the small-scale extraction. The yield of HE extract in the 
2nd and 3rd hot water extraction were 41.87%，6.87% and 2.78%, respectively, of 
the dry weight of the desugared H. erinaceus powder. All the crude extracts were 
pooled together and deproteinized by the Sevag treatment to give a deproteinized 
polysaccharide fraction (HE-DP), with 9.30% recovery from the total crude 
extract. 
The yield of polysaccharides in the large-scale extraction is tabulated in table 3.2. 
Desugared H. erinaceus powder (1613.17 g) was extracted by hot water 2 times. 
After the hot water extract was stored at low temperature (4°C) overnight, a 
gel-like cold water insoluble fraction was collected by centrifugation. After 
lyophilization, the weight of the gel-like substance was 541.18 g, i.e. 33.55% 
yield. The supernatant (soluble fraction) was subjected to sequential treatments 
including ultrafiltration, dialysis and lyzophilization, which gave a yield of 
2.34% of the HE-CS. A portion of the gel-like cold water insoluble fraction was 
then re-dissolved in hot water, followed by dialysis and lyophilization, to 
generate the fraction HE-CI. The recovery of HE-CI from the cold water 
insoluble fraction was 5.57%. Theoretically, based on the recovery of HE-CI, the 
total amount of HE-CI that could be extracted from the entire gel-like cold water 
insoluble substances should be 30.12 g (541.18 g x 5.57%), with a yield of 
75 
1.87% of the 1.6 kg desugared H. erinaceus powder. In order to compare the 
effect of removal of protein from the HE polysaccharides on their hypoglycemic 
effect，a portion of HE-CS was deproteinized by the Sevag treatment to give the 
fraction HE-CSD, which gave a yield of 57.18%. 
Hot water extraction was selected to isolate the polysaccharides from the fruiting 
body of H. erinaceus because antidiabetic studies of the other blood-glucose 
lowering fungal polysaccharides extracted from G. lucidum (Hikino et al., 1985), 
T. auranita (Kiho et al., 1995) and A. auricula (Yuan et al., 1998a; Yuan et al” 
1998b) as well as Agrocybe cylindracea (Kiho, Sobue and Ukai, 1994) were 
conducted using hot water extract. Thus a similar extraction scheme was adopted 
for the antidiabetic active polysaccharides from the fruiting body of H. erinaceus. 
In addition, several studies on the structural features of HE-polysaccharides also 
employed hot water as extractant (Mizuno et al, 1992; Mori et al., 1998 and 
Wang, Luo and Liang, 2004). Thus, to facilitate comparison, it would be better to 
extract the HE-polysaccharides with similar procedure. 
The most common way to consume H, erinaceus is to use it as a soup ingredient. 
In other words, daily consumption of H. erinaceus is in the form of hot water 
extract. Therefore, study of the antidiabetic effect of the hot water-extracted 
polysaccharides of H. erinaceus can better be correlated with improvement of 
glucose tolerance through dietary consumption. 
The HE powder was desugared with 85% (w/v = 1 g : 20 ml; yield of desugared 
HE powder: 59.36%) as well as 95% ethanol (w/v = 1 g : 7ml; yield of desugared 
76 
Table 3.1 Yield of Small-scale Hot Water Extraction 
Dry Weight (g) Yield (%) 
Desugared HE powder for extraction 25.22 
pt crude extract 10.56 41.87 
2nd crude extract 1.734 6.872 
3rd crude extract 0.700 2.775 
Total crude extract 12.99 51.52 
Deproteinized HE polysaccharide 
1.208 9.295 
(HE-DP) 
Table 3.2 Yield of Large-scale Hot Water Extraction  
Dry Weight (g) Yield (%) 
Extraction of HE-CS 
Desugared HE powder for extraction 1613 … 
HE-CS extracted 37.68 2.336 
Cold water insoluble gel substances^ 541.2 33.55 
Deproteinization of HE-CS 
HE-CS for deproteinization 9.42 
HE-CSD collected 5.39 57.18 
Extraction ofHE-Cl'^ 
Cold water insoluble gel substances 52.41 — 
HE-CI extracted 2.919 5.569 
a. this refers to the cold water insoluble fraction collected as pellet after 
refrigeration, as shown in figure 2.3 b. this process was re-dissolving the cold 
water insoluble fraction, as shown in figure 2.3b. 
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HE powder: 79.23o/o) in the small- and large-scale extraction, respectively. The 
removal of small molecular weight substances by ethanol was necessary before 
hot water extraction due to a relatively high level of these substances present in 
the fruiting bodies of H. erinaceus, such as monosaccharides and hercenon 
(Mizuno, 1999). When a small-scale extraction was conducted without ethanolic 
treatment, the extract after lyophilization was crystalline, granular and sticky in 
nature, which was different from the soft and layer-like structure of 
polysaccharides obtained from desugared HE powder. Thus, desugaring to 
remove small molecular weight substances was necessary before extraction of 
HE polysaccharides. 
From table 3.1, the total yield of hot water extracted polysaccharides was 51.52% 
of the dry weight of desugared HE powder. The amount of the crude extract 
accounted for about 81.29% of the total crude extract while the and crude 
extracts constituted only 13.32% and 5.39%, respectively, of the total. Thus for 
practical considerations, only two extractions were conducted in large 
scale-extraction. Theoretically, two hot water extractions could collect about 94% 
of total hot water-soluble matter from the fruiting body of H. erinaceus. 
The aim of milling the mushroom into 1 mm powder in large-scale extraction 
was to increase the surface area for extraction. However, this process also 
increased the difficulty in sample handling. During extraction, the HE powder 
settled to the bottom of the container despite continuous mechanical stirring. The 
sedimentation of the HE powder would interfere with heat transfer as well as 
mass transfer in the whole set up, decreasing yield of the extraction. Moreover, 
very fine particles also caused a problem during separation of the soluble extract 
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and the residue. To solve this problem, instead of milling, the mushrooms should 
be blended into a pomace by adding water before boiling. 
Edible mushrooms contain p-glucan with P(l+3)，P(l+4) and 6) 
glucosidic linkages, and they have been known for their health benefits, such as 
antitumour and hypocholesterolemic (Manzi and Pizzoferrato, 2000). One of the 
fungal P-glucans, (1^6)-branched (l->3)- P-glucan is generally characterized by 
its gel-forming ability which results in the formation of a single- or triple-helical 
structure (Saito et al., 1981; Ohno et al., 1986). This might provide an 
explanation for the formation of a gel-like cold water insoluble substance after 
keeping the hot water extract at 4°C. 
3.2 Physico-chemical Properties of HE Polysaccharides 
3.2.1 Carbohydrate, Protein and Uronic Acid Content 
The carbohydrate, protein and uronic acid content were measured by the 
phenol-sulfuric acid method, Lowry assay and the official method adopted from 
the A.O.A.C., respectively. Table 3.3 shows the sugar, protein and uronic acid 
contents in HE-DP, HE-CS, HE-CSD and HE-CI. The carbohydrate contents of 
these 4 fractions range from 74.04% in HE-CI, to the highest level of 86.40% in 
HE-CSD, but they are not significantly different from each other. Concerning the 
protein level, HE-DP fraction has the highest level of protein (13.86%), while 
HE-CS and HE-CI have 9.93% and 6.90% protein, respectively. After 
deproteinization，HE-CSD still contains about 8.71% peptide moiety, which is 
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significantly lower than HE-CS. For the amount of uronic acids, the level in 
HE-DP (3.26%) is significantly higher than that in HE-CS (1.95%), HE-CI 
(1.19%) and HE-CSD (2.36%). 
Table 3.3 Sugar, Protein and Uronic Acid Contents in the 
HE-Polysaccharides^ 
HE-DP HE-CS HE-CSD HE-CI 
Sugar (%) 79.67 士 4.47' 74.97 士 6.39a 86.40 士 1.50' 74.04 士 4.39a 
Protein (o/o) 13.86 土 0.04a 9.93 士 0.53b 8.71 士 0.12� 6.90 士 0.2ld 
Uronic acid (%) 3.26 士 0.02a 1.95 士 0.09b 2.36 土 0.07� 1.19 士 O.OQd 
a. Data are means 士 standard deviations. The mean values within the same row with different 
superscripts were significantly different at p < 0.05 
These data imply that HE-polysaccharides were protein-bound polysaccharide 
complexes. From the study by Mizuno et al. (1992), the hot water extract of H. 
erinaceus contains 4 polysaccharides (fractionated by DEAE-cellulose 
chromatography, Toyopearl HW-65F gel filtration，and Con A-AF-Toyopearl 650 
affinity chromatography), and their sugar, protein and monosaccharides 
components are tabulated in table 3.4. The sugar content of the 4 polysaccharides 
ranged from 40.5% to 89.7% and the protein level was between 4.2% and 51.5%. 
One of the four polysaccharides, FI�-a-a w s a xylan-protein complex. In another 
study on H. erinaceus by Wang and et al. (2004), HPA and HPB were two 
polysaccharides isolated from the fruiting body by hot water extraction. HPA is a 
heteroglycan of 100% carbohydrate consisting of glucose, galactose and fucose; 


































































































































































































is protein. From these two studies, polysaccharides extracted from the fruiting 
body of H. erinacues were shown to be protein-bound polysaccharide complex. 
Several polysaccharides that possess medicinal functions, especially antitumour 
activity, are the protein-bound polysaccharide complexes. One of the well-known 
antitumour polysaccharide-protein complexes is from Coriolus versicolor, 
known as PSK (Ooi and Liu, 2000). PSK contains 25-38% protein with an 
average molecular weight of 94x10^. The dominant amino acids found in PSK 
are aspartic acid and glutamic acid; neutral amino acids such as valine and 
leucine and a small amount of basic amino acids such as lysine and arginine were 
also found (Ooi and Liu, 2000). From the fruiting body of Agaricus blazei, a 
water-soluble P-(l->6)-D-glucan protein complex (polysaccharide : protein = 50 : 
43 w/w) with significant antitumour activity was extracted (Mizuno et al., 1995b). 
Another antitumour protein-bound polysaccharide, P-glucan-protein (EA6),was 
isolated from the fruiting body of Flammulina velutipes. It contains 70% 
polysaccharides and 30% protein, containing glucose, galactose, mannose, xylose, 
arabinose, and 16 amino acids (Ikekawa et al., 1995). It acts strongly against 
tumor cell lines such as Sarcoma 180, Lewis cancer of lung and B-16 melanoma. 
HE-DP, HE-CS as well as HE-CI all contain uronic acid in their structure.The 
antidiabetic polysaccharide (TAP) isolated from T. aurantia is an acidic 
polysaccharide, consisting of mannose, xylose, glucuronic acid and glucose in a 
molar ratio of 4 : 2 : 1 : 0.3，with a side chain constituted of p-D-glucuronic acid 
linked to terminal a-D-mannopyranose (Kiho et al., 2000a). Although all the 
HE-polysaccharides contain uronic acids, their level of it is relatively low (less 
than 4%) and thus HE-polysaccharides would adopt a structure different from 
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that of TAP. 
3.2.2 Monosaccharide Compositions 
The monosaccharide compositions of HE-DP, HE-CS and HE-CI are listed in 
table 3.5. For HE-DP and HE-CS, glucose and galactose are the two main sugars, 
constituting over 85% of total monosaccharide composition. The glucose and 
galactose levels in HE-DP are 67.03% and 18.19%, respectively; while for 
HE-CS, they are 63.70% and 23.98%, respectively. In HE-DP, glucosamine 
(5.81%) and fucose (5.34%), and mannose (2.31%) were also found. Tthe 
remaining sugars accounted for less than 1% of total sugar composition. Fucose, 
mannose and glucosamine are the other 3 major sugars found in HE-CS after 
glucose and galactose, at a level of 6.25%, 2.65% and 2.77%, respectively. The 
composition of HE-CI is very different from the other 2 fractions, having a 
higher level of glucose (up to 89.05%). Galactose was also identified in HE-CI, 
but at a much lower level (3.83%) than HE-DP and HE-CS. 
Table 3.4 shows sugar level, protein content, sugar components and molecular 
weights of HE polysaccharides studied by Mizuno et al. (1992). The major 
monosaccharide found in the 4 hot water extracted polysaccharides is xylose, 

































































































































































































In a structural study of HE polysaccharides, two polysaccharides, AF2S-2 and 
BF2S-2, were obtained by autoclaving (117kPa) the fruiting body with hot water 
at 1 2 r C (Mori et al., 1998). Glucose is the main monosaccharide present (over 
90%) with a little mannose and fucose (Mori et al., 1998). Details were shown in 
table 3.6. 
From the study of hot water extracted HE-polysaccharides (HPA and HPB) by 
Wang and colleagues (2004), HPA contained glucose, galactose and fucose in a 
ratio of 1 : 2.110 : 0.423; while galactose and glucose were found in HPB in a 
ratio of 1 : 11.529. 
Table 3.6 Monosaccharide Composition and Molecular Weight of HE 
polysaccharides (adapted from by Mori et al. 1998) 
AF2S-2 BF2S-2 
D-Glucose 96.3% 95.7% 
D-Mannose 2.8% 3.1% 
L-Fucose 0.9% 0.6% 
Molecular Weight 13,000 22,000 
3.2.3 Molecular Weight of the HE polysaccharides 
The log values of the molecular weight of the pullulan standards were plotted 
against the retention time (minutes) as shown in figure 3.1. The molecular 
weights of HE-CS and HE-CI were calculated by the linear formula provided in 
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Figure 3.2a The GPC chromatogram of HE-CS (Progel™-TSK column of 
G6000 PW, 30 cm length X 7.5 mm i.d.; eluent: 0.2M NaCl at 1 ml/min at 
25"C) 
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Figure 3.2b The GPC chromatogram of pullulan standards and HE-CS. Red 
line: P-400 (MW. 40.4 X 10"^ ); Green line: P-10 (MW. 1.18 X 10 )^; Blue: 
HE-CS (conditions as seen in figure 3.2a) 
87 
Refractive Index 2 




113: ^ ~ 
, , , , , , X -~ r — r — ‘ T—了 r ' ' ' ' ' 0 1 _1P 15 20 _ 
Time (min) 
Figure 3.3a The GPC chromatogram of HE-CI (Progel^^-TSK column of 
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Figure 3.3b The GPC chromatogram of pullulan standards and HE-CI 
Red line: P-10 (MW. 1.18 X 10^); Blue: HE-CI (conditions as seen in figure 
3.3a) 
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Two peaks, one major and one minor (83% and 16%, respectively), were found 
in HE-CS and their retention times were 11.2 and 13.3 min, with respective 
molecular weights of 432,100 and 12,600. The chromatogram of HE-CI (figure 
3.3a and 3.3b) revealed one major component at 13.4 min. The molecular weight 
was found to be 9,800. However, a shoulder peak seemed to be present, 
suggesting that two polysaccharides with similar molecular weights were not 
completely fractionated by the column. 
Comparing the molecular weight of HE-CS and HE-CI to those of the four hot 
water extracted antitumour polysaccharides from H. erinaceus in table 3.4，the 
molecular weights of HE-CS and HE-CI are much smaller except the 
polysaccharide in the HE-CS fraction that has a molecular mass of 432,100. 
From table 3.6, it shows different results on the determination of molecular 
weight of hot water extracted HE polysaccharides. The molecular weights of the 
2 polysaccharides (AF2S-2 and BF2S-2) from H. erinaceus are 13,000 and 
22,000，respectively (Mori et al., 1998). And in the Wang and colleagues study 
(2004), the molecular weights of HPA and HPB are 50,000 and 30,000, 
respectively. Thus the present findings on the molecular weight of the major 
HE-polysaccharides were consistent with those of the HE-polysaccharides 
studied by Mori et al. (1998) and Wang et al. (2002), but differed from the results 
of the molecular weight of the 4 antitumour HE-polysaccharides reported by 
Mizuno and colleagues (1992). 
89 
3.2.4 Structure of HE polysaccharides 
Methylation analysis (table 3.7) revealed that the structure of HE-CS is mainly 
built up by 1,3-linked galactopyranose， 1,6-linked glucopyranose and 
1,2,6-linked galactopyranose, with a molar ratio of 0.20 : 1.0 : 0.23. A minority 
of 1,4-glucopyranosyl and 1,3,6-mannopyranosyl linkages also contributes to the 
conformation of HE-CS. For the structure of HE-CI, 1,3-, 1,4-, 1,6-linked 
glucopyranoses are present in the polysaccharides, with 1,3-glucopyranosyl 
linkage being the most dominant. Besides glycosidic linkages, substantial 
amount of 1,3,6-mannopyranosyl linkages (molar ratio: 0.47) and a little of 
1,6-galactopyranosyl linkages (molar ratio of 0.08) were also found in HE-CI. 
Figure 3.4 and 3.5 show the GC-MS spectra of HE-CS and HE-CI, respectively. 
From the methylation analysis of HE-CS, 1,6-glucopyranosyl linkage is the most 
dominant followed by 1,3-galactopyranosyl and 1,2,6-galactopyranosyl linkages. 
Due to the presence of 2 polysaccharides in HE-CS, the exact structure of the 2 
polysaccharides could not be accurately deduced. However, a brief deduction of 
the plausible structure of HE-CS was proposed as follows. As 1,6-glucopyranosyl 
linkage is dominant, it is possible that the backbone of the 2 polysaccharides in 
HE-CS is built by (l->6)-linked glucopyranosyl backbone. The molar ratio of 
1,6-linked glucopyranose to 1,2,6-linked galactopyranose was close to 5 : 1. 
Theoretically the 1,2,6-linked galactose appears in every 5 glucose molecules 
and forms the branching point. This gives a highly-branched structure of HE-CS 
and the branches of HE-CS probably contained a straight chain of l，3-linked 
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Figure 3.4 GC-MS Spectrum of HE-CS 
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Figure 3.5 GC-MS Spectrum of HE-CI 
GC-MS conditions (for GC chromatograms in Figure 3.4 and 3.5)  
GC Part HP-5MS capillary column (5% phenyl methyl siloxane, 30m * 25\im i.d.); 
carrier gas: helium (flow rate: 1.2 ml/min); Oven temperature (initial temp.: 130�C, final 
temp.: 280®C, temp, increase rate: 3°C/min); Interface temperature: 250°C; Split ratio: 
30:1 MS Part: Ion source temperature: 250®C; Ionization energy: 70eV; Volts of 
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possibly constitute the backbone of HE-CI with substitution of 1,3,6-linked 
mannopyranosyl for every 2 glucose moiety to form the branching point. The 
1,4-glucopyranosyl and 1,6-glucopyranosyl residues would possibly form the 
side chains of HE-CI. The partial structure of HE-CI is shown in figure 3.7. 
3Glcl —3Glcl -^3Manl -^3Glcl -^SGlcl •^3Manl->6Glcl —6Glcl ->3Manl — 
6 6 6 
i 丄 i 
1 1 1 Glc-(l->6)Glc Glc-(l->4 )Glc Glc-(1—6)Glc 
Figure 3.7. Partial Structure of HE-CI 
P-(l->3), (1—4) and (l->6) glycosidic linkages are common linkages found in 
beta-glucans of mushrooms. Fungal homo- and heteroglycans containing 
(3-(1->3), (1—4) and (1—6) glycosidic linkages are supposed to contribute to the 
health improving functions of mushrooms. For instance, two most well known 
antitumour active polysaccharides, lentinan from Lentinus edodes and 
schizophyllan from Schizophyllum commune are constituted primarily of a 
(l->3)-linked glucan backbone with (1—6)-linked side branches (Ooi and Liu, 
2000). The fruiting body of Auricularia auricula-judae contained antitumour 
active (1+3)爷 glucan (Misaki and Kakuta, 1995) and an antitumour active 
heteroglucan with P-(1^3)-linked main chain attached with (1—6)-p-glucosyl 
braches was extracted from the fruiting body of Panellus serotimus (Ma, Mizuno 
and Ito, 1991). Thus, the presence of P-(l->3), (1+4) and (1+6) glycosidic 
linkages in HE-CS and HE-CI would be highly probable. 
From the study of Mizuno et al. (1992), FI�-a-p and FI�-a-a, 2 of the 4 hot water 
extracted HE polysaccharides have p-(l->3) and (1—6) glucan chains; while 
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from the study of Mori et al. (1998)，it was found that the hot water-extracted 
polysaccharides contained a main chain of p-(l->6) linkages with side chains of 
p- (1^3) linkages. 
Figure 3.8 shows the partialstructure of polysaccharides isolated from H. 
erinaceus suggested by Mori and colleagues (1998). In HE-CS, only (l->6) 
glucopyranosyl glycosidic linkage was found which probably forms the 
backbone of the polysaccharide, but with very little P - ( D 3 ) linkages. For 
HE-CI, despite the presence of (1—3) and (l->6) glycosidic linkages, the 
structure seems to be more complicated from the one proposed by Mori and 
colleagues due to the presence of substantial amount of mannose and some 
6 galactose residues. 
CH2 P ~ C H 2 p — C H 2 P"•… 
CH20Hp 
H 口 1 
/ OH 
Figure 3.8 Partial Structure proposed for AF2S-2 and BF2S-2 (adapted from 
Mori et al., 1998) 
The investigation on the structure of HE polysaccharides, HPA and HPB, by 
Wang et al. (2004) reveals another architecture. HPA has a backbone composed 
of (1 ^6)-linked-galactose with branches attached to 0-2 position of some 
galactose. The branches are composed of (1 ->6)-linked-glucose, 
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(l->3)-linked-glucose and (1^4)-linked-fucose. (figure 3.9a). For HPB (figure 
3.9b), there are some similarities with the structures of AF2S-2 and BF2S-2 
suggested by Mori et al. (1998), with a (l+6)-linked-glucose backbone and 
branching at position 3 of the glucose moiety. The branches contain 
(l-^3)-linked glucose and (1^6)-linked galactose attached to a glucose terminal. 
Figure 3.7b shows the partial structure of HPB. 
6 ^ ) - G a l - ( 1 ->6) -Gal - ( 1 —6)-Gal- ( 1 ->6)-Gal- ( 1 ->6)-Gal- ( 1 ->6)-Gal-( 1 —6)-Gal - ( 1 -^6) -Gal - ( 1 ->6) -Gal - ( 1 
— > 
2 2 2 i i ^ 
1 1 1 
G a l - ( l - » 4 ) - F u c G1C-(1^3)-G1C2 G a l - ( l - » 6 ) - G l c 3 
Figure 3.9a Partial Structure ofHPA (Wang et al., 2004) 
6 ^ ) - G l c - ( 1 ->6) -Glc- ( 1 —6)-Glc- ( 1 ~>6)-Glc-( 1 ~>6)-Glc-( 1 -^6)-Glc- ( 1 ->6) -Glc- ( 1 - > 
3 3 3 
； i i 
1 1 1 
Glc Glc - (1—6)-Gal Glc- (1—3)-Glc2 
Figure 3.9b Partial Structure of HPB (Wang et al” 2004) 
3.2.5 Conclusion for the Physico-chemical Properties of HE-Polysaccharides. 
Table 3.8 is a summary of the physico-chemical properties of HE-CS and HE-CI. 
The physico-chemical properties of HE polysaccharides have been studied by 
different groups of scientists (Mizuno et al., 1992; Mori et al., 1998; Wang et al., 
2004). However, different structures were proposed by the authors and it is hard 
to decide on a universal structure. Variations in extraction conditions and 
separation methods are the main factors contributing to these structural 
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differences. 
The antitumour polysaccharides studied by Mizuno et al (1992) were pre-treated 
with 85% ethanol at 30°C for 24 h. The residue was extracted with hot water at 
100°C for 3 h, and then fractionated by DEAE-cellulose chromatography, 
Toyopearl HW-65F gel filtration chromatography, and Con A-AF-Toyopearl 650 
affinity chromatography. 
In the study of Mori et al. (1998), the HE-polysaccharides were first extracted 
with water at 4°C, followed by hot water in an autoclave (117kPa) at 121°C. The 
polysaccharides were deproteinized by the addition of ammonium sulphate. Then 
the polysaccharide was submitted to DEAE-Sephadex A-50 column, eluted with 
water, followed by 0.2 M NaCl. 
Wang and colleagues (2002) extracted HE-polysaccharides with 1 L hot water at 
100°C for 2 h. All the extracts were then pooled together and dialyzed against 
running water for 48 h. The extract was then separated by fractional precipitation 
with ethanol and dried at 45°C at reduced pressure to give the crude 
polysaccharide. The crude polysaccharide was deproteinized by adding 
proteinase followed by the Sevag treatment. Finally, the deprotinized 
HE-polysaccharide was further decolourized by H2O2 Separation of the crude 
polysaccharides was by size-exclusion chromatography. The samples were 
dissolved in water and injected into a column of DEAE-Sepharose CL-6B 
equilibrated with 0.9% NaCl. The column was eluted with 0.15 M and 3.9 M 
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aqueous NaCl solution. The HPA and HPB fractionscollected were then further 
purified by gel filtration on a column of Sephadex G-100. 
Despite the use of hot water to extract the HE-polysaccharides, the difference in 
the extraction conditions as well as the subsequent fractionation schemes would 
result in the collection of different hot-water soluble polysaccharides from H. 
erinaceus. Moreover, HE-CS and HE-CI would probably not a homogenous 
polysaccharide and so the present findings might be different from the previous 
studies. 
Table 3.8 Summary of the Physico-Chemical Properties of HE-CS and 
HE-CI 
HE-CS HE-CI  
Cold Water Solubility Soluble Insoluble 
Molecular Weight 432,100 & 12,600 9,800 
Glucose (63.70%) Glucose (89.05) Monosaccharide , … … , , … 0 Galactose (23.98) Glucosamine (4.41) 
Content (%) Fucose (6.25%) Galactose (3.83) 
Structure (1^6)-linked Glucopyranosyl (1^3)-linked Glucopyranosyl 
Backbone Backbone 
Branching Point: Position 2 of Branching Point: Position 6 of 
(1^6)-linked galactose (1^3)-linked mannose 
OR 
(1 ->6)-linked Glucopyranosyl 
Linear Structure 
Protein Level (%) 9.93 6.90 
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3.2.6 Viscosity of HE Polysaccharides 
HE-CS and HE-CI were reconstituted in distilled water to measure their viscosity. 
The viscosity of HE-CS at 33.33 mg/ml is 8.38 centistokes and that of HE-CI at 
3.33 is 66.36 centistokes. When compared to the efflux time of distilled water, on 
the same concentrations (33.33 mg/ml of HE-CS and 3.33 mg/ml of HE-CI),, the 
specific viscosity (r|) of HE-CS and HE-CI are 9.15 and 72.52, respectively. The 
results are shown in table 3.9. 
The viscosity of a polymer solution depends on the size and shape of the 
molecules in the solvent system. Generally, a linear polysaccharide in solution 
flexes and sweeps out for more space, and thus collides with each other, 
generating friction and consuming energy, and so gives a solution of high 
viscosity. On the other hand, a highly branched polysaccharide flexes and sweeps 
for less space than a linear polysaccharide, thus a branched polysaccharide gives 
a less viscous solution than a linear one at the same molecular weight. At the 
same time, molecular weight also influences the viscosity of a solution, a high 
molecular weight polysaccharide produces a solution of higher viscosity that a 
low molecular weight one (BeMiller and Wistler, 1996). 
Based on the above principle, the structure of the HE-CS and HE-CI can be 
deduced from their viscosity. HE-CI has a much higher viscosity than HE-CS, 
but the molecular weight of HE-CI (9,800) is lower than that of HE-CS. Thus，in 
order to produce a highly viscous solution, linearity of the structure of HE-CI 
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should be higher than that of HE-CS which is theoretically more 
highly-branched. 
The high viscosity of HE-CI implies a potential for lowering the postprandial 
blood glucose by this fungal polysaccharide. The viscous nature of 
polysaccharide solution is believed to be the dominant characteristics to delay 
glucose absorption. Guar gum, one of the most viscous naturally-occurring 
polysaccharides, was shown to be effective in improving glucose tolerance in 
human (Blackburn et al., 1984a; Edwards et al., 1987). 
In order to evaluate the potency of HE-CI and HE-CS to reduce postprandial 
hyperglycemia, in vitro tests and oral glucose tolerance tests were conducted. 
Table 3.9 Viscosity of HE-CS and HE-CI 
Average 
Cone. Viscosity Specific 
efflux time 
(mg/ml) (centistokes) viscosity Ol)  
(secO  
HE-CS 33.33 558.33 8.38 9.15 
HE-CI 3.33 4424 66.36 72.52 
Distilled water --- 61 --- ---
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3.3 In vitro Study of the Hypoglycemic Effect of HE-Polysaccharides 
3.3.1 Glucose Dialysis Retardation Index (GDRI) 
Table 3.10 shows the glucose concentrations in the dialysate and GDRI values of 
1% alginic acid, 2% HE-CS and 0.5% HE-CI over a time period of 360 min. The 
presence of 1 % alginic acid significantly inhibits the diffusion of glucose at 60, 
120，180，300 and 360 min, with the highest GDRI value observed at 60 min. At 
0.5% concentration, HE-CI significantly lowers the glucose diffusion rate from 
20 to 360 min. The GDRI values of HE-CI at 60, 90，120 and 150 min are over 
40. The HE-CS fraction inhibits the glucose diffusion with a GDRI of 20.69 at 
120 min. Figure 3.10 shows the glucose concentration of alginic acid and HE-CI 
at different time periods. Alginic acid and HE-CI exert a more consistent 
inhibition on glucose diffusion when compared to the control. However, for the 
HE-CS fraction，the glucose concentration of the dialysate fluctuated over time, 
but generally it is quite similar to the control. 
GDRI is an ideal in vitro index to estimate the effect of fiber in delaying glucose 
absorption in the small intestine. The GDRI value was calculated by the 
following formula: 
=100 - [(glucose content in the dialysate containing the polysaccharide/glucose 












































































































































































































































































































































































































































































































































































































































































































































As expected, the highly viscous HE-CI solution impeded the diffusion of glucose 
out of the dialysis tubing. At 90 min, the glucose concentration of the dialysate 
containing HE-CI is only 55% of the control. Moderate viscous 1% alginic acid 
could also interfere with glucose diffusion. Similar trends were shown by the 
GDRI values of alginic acid and HE-CI. GDRI was increased from the beginning 
to the highest values at 90 min and 60 min for HE-CI and alginic acid, 
respectively. 
Therefore, the viscous nature of the polysaccharides (HE-CI and alginic acid) 
was expected to slow down glucose diffusion across the dialysis tubing, resulted 
in an elevation of GDRI values of HE-CI and alginic acid groups. However, as 
time elapsed, glucose content in the dialysate of the control approached an 
equilibrium, and amount of accumulated glucose in the dialysate of the HE-CI 
and alginic acid groups increased, resulted in a reduction in GDRI values. 
Another explanation proposed by Ou and colleagues (2001) was the adsorption 
of glucose by the polysaccharides. At the beginning, glucose molecules were 
attached on the surface of the polysaccharides and the viscosity of the solution 
blocked the glucose diffused across the dialysis membrane. The combined effect 
of adsorption and viscosity caused an elevation in GDRI values. However, as 
time elapsed, adsorption of glucose on the polysaccharides became saturated and 
viscosity was the sole factor affecting glucose diffusion, thus the GDRI values 
decreased. 
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3.3.2 Inhibition of a-Amylase Activity 
The maltose concentrations of the dialysate of alginic acid, HE-CS and HE-CI at 
different time periods are shown in table 3.11. HE-CS did not show significant 
inhibition on a-amylase activity, while alginic acid showed significant inhibition 
at 20, 30, 120，150 and 180 min. When the inhibition at 20 minutes is not 
considered (as the values are negative), the most significant inhibition was found 
at 30 min, with a-amylase completely inhibited by 1% alginic acid. At 180 min, 
alginic acid still inhibited a-amylase by 32.93%. Inhibition of a-amylase activity 
by HE-CI was found at 20, 120, 150 and 180 min, with the highest inhibition 
found at 20 min. The maltose concentration of the alginic acid group was lower 
than the control throughout the test and the HE-CI group also shows a similar 
trend except at 60 min when the maltose concentration of HE-CI was higher than 
the control. The maltose concentration of the HE-CS group increased with time, 
and was higher than that of the control at 60，150 and 180 min. 
In this experiment, HE-CS was ineffective in inhibiting a-amylase activity. 
HE-CI only significantly inhibited a-amylase at 120, 150 and 180 minutes. 
Isaksson and colleagues (1982b) analyzed the effect of 5 factors of dietary fiber 
on pancreatic enzyme activity. They are: viscosity, pH, ionic strength, adsorption 
and time of incubation. 
The increase in the viscosity of the medium (i.e. duodenal juice) by the addition 
of fiber caused a reduction in pancreatic enzyme activity such as amylase, trypsin, 
lipase and phospholipase (Isaksson et al” 1982b). A highly viscous medium 

































































































































































































































































































































































































































































































































the rate of digestion (Jenkins et al., 1978). The reduction of enzyme-substrate 
contact would also be caused by adsorption of enzyme by the fiber. In the study 
by Isaksson and colleagues (1982b), trypsin was adsorbed on wheat bran. 
The change of pH in the surrounding environment of the enzyme could decrease 
the efficiency of converting the substrates into products. In an in vitro test 
(Isaksson et al., 1982b), addition of low methylic esterification pectin and high 
methylic esterification pectin caused the change of pH from 5.7 to 3.9 and 5.7 to 
5.3, respectively. When the pH of duodenal juice was adjusted to 3.9, the 
activities of pancreatic a-amylase, trypsin and lipase were affected. 
Isaksson and colleagues (1982b) proposed that small changes in ionic strength 
did not modify pancreatic enzyme activity, while during incubation, the 
inhibitory effect on enzyme activity by fiber occurred within a short period of 
time. For instance, half of the enzyme-inactivating effect of low methylic 
esterification pectin over 60 min could be reached within 10 min. 
Viscous nature of HE-CI should contribute to the inhibition of a-amylase activity. 
However, the inhibition by HE-CI was only significant at 20, 120, 150 and 180 
min after the start of the experiment. The insignificant inhibition at the beginning 
of the experiment may be explained by uneven distribution of a-amylase. The 
viscous HE-CI solution hindered even diffusion of the enzyme, resulted in 
regional localization of the a-amylase on the upper-part of the HE-CI solution. 
Therefore, in regions with higher amount of a-amylase, starch was immediately 
broken down into maltose which diffused out very quickly (at the first 20 min). 
Afterwards, the inhibition was not significant. Other factors such as changes of 
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pH and adsorption of enzyme may inhibit enzyme activity. However, their effects 
were only significant 2 hafter the start of the experiment. 
For better understanding of the inhibitory action of HE-polysaccharides on 
enzyme activity, it is recommended to measure the viscosity and pH of the 
polysaccharides mixtures in the dialysis tubing during the experiment. Also, the 
adsorption feature of the polysaccharides should be evaluated. A similar setup to 
the measurement of GDRI should be used, and after reaching the adsorption 
equilibrium, the glucose content in the dialysate should be determined. The value 
should then be subtracted from the glucose content in the retentate before the 
start of the experiment and the difference is the adsorption capacity of the 
polysaccharides. 
In another study of the in vitro inhibition of pancreatic enzymes by dietary fiber 
(Isaksson et al., 1982a), the authors reported that the inhibition was more potent 
when tested in human duodenal juice rather than in a conventional buffer system. 
The protein content (such as the presence of albumin), pH, ionic strength and 
hormonal profiles in the conventional buffer are different from those in human 
duodenal juice. Human duodenal juice is a more suitable environment for the 
pancreatic enzymes to function. Therefore, the use of human duodenal juice can 
improve the present in vitro test. 
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3.4 In vivo Hypoglycemic Evaluation of HE-Polysaccharides 
3.4.1 In vivo Oral Glucose Tolerance Test (OGTT) in Normal Mice 
3.4.1.1 Oral Glucose Tolerance Test 
A mixture of HE-CS and glucose was fed to female BALB/c mice at a dosage of 
0.5 g HE-CS and 1 g glucose per kg body weight. This dosage did not 
significantly suppress the rise in blood glucose (figure 3.11). The levels of 
postprandial blood glucose at all time periods were not significantly different 
from that of the control. Despite an increase in dosage of HE-CS to 1.5 g per kg 
body weight (figure 3.12), the same trend resulted. In these two tests, glucose 
concentration peaked at 30 min after feeding, and glucose concentrations of the 
two HE-fed groups are higher than the control, but the differences are not 
significant. 
The test was also conducted on male BALB/c mice at a dosage of 1 g HE-CS per 
kg body weight (figure 3.13). However, HE-CS was still unable to lower blood 
glucose level after glucose loading. The plasma glucose levels at all times are 
close to the control. 
In OGTT, HE-CI was fed to female BALB/c mice at a dosage of 0.15 g per kg 
body weight (figure 3.14).The blood glucose level was not significantly 
decreased after feeding HE-CI and glucose simultaneously. The glucose peak 
was attained 30 min after feeding and the level of the HE-CI-fed group, (206.67 
士 31.09 mg/ml), was close to that of the control, (197.98 士 34.43 mg/ml). The 
plasma glucose levels are slightly lower than control at 120 (control: 137.53 士 
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Figure 3.11 Oral Glucose Tolerance Test of HE-CS fed to the 8-9 week old of 
female BALB/c mice at a dosage of 0.5 g/kg body weight of mice 
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Figure 3.12 Oral Glucose Tolerance Test of HE-CS fed to the 8-9 week old of 
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Figure 3.13 Oral Glucose Tolerance Test of HE-CS fed to the 8-9 week old of 
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Figure 3.14 Oral Glucose Tolerance Test of HE-CI fed to the 8-9 week old of 
female BALB/c mice at a dosage of 0.15 g/kg body weight of mice 
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Figure 3.15 Oral Glucose Tolerance Test of HE-CI fed to the 8-9 week old of 
female BALB/c mice at a dosage of 0.4 g/kg body weight of mice 
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27.72 mg/ml, HE-CI group: 128.83 士 16.07 mg/ml) and 180 minutes (control: 
148.30 土 27.57 mg/ml, HE-CI group: 129.27 士 20.87 mg/ml), without any 
statistical significant differences. Despite an increase in dosage to 0.4 g, HE-CI 
did not improve the glycemic response of the mice to glucose loading (figure 
3.15). 
In OGTT, both HE-CS and HE-CI did not reduce postprandial hyperglycemia. As 
HE-CS was highly soluble in aqueous medium, it is not surprising that the results 
are negative since viscosity of the polysaccharide is the main factor to reduce 
postprandial hyperglycemia. A highly viscous polysaccharide can delay the 
gastric emptying time and decrease the absorption of glucose in the small 
intestine (Blackburn et al., 1984a; Elsehans et al., 1981; Holt et al., 1979; 
Johnson and Gee, 1981; Torsdottir et al., 1989). Thus, polysaccharides with low 
viscosity such as HE-CS, are expected to be ineffective in reducing postprandial 
hyperglycemia. 
Viscosity measurements, in vitro tests of HE-CI on the retardation of glucose 
diffusion, and inhibition a-amylase activity, all indicate that HE-CI has the 
potential to ameliorate hyperglycemia. However, in the present finding, HE-CI 
could not lower the blood glucose level after glucose loading. The discrepancy is 
not fully understood although the difference between in vivo gastrointestinal 
environment of the animal and the simulated in vitro tests might partly explain 
this. 
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3.4.1.2 Effect of Change of Viscosity of HE Polysaccharide in the GI Tract of 
Mice 
As mentioned in section 1.2.1, digestion of foods starts from the mouth, and then 
continues as foods pass through the stomach and transit to the small intestine 
consisting of duodenum, jejunum and ileum. In the stomach, the environment is 
acidified by the secretion of hydrochloric acid to provide the optimum pH for 
pepsin. Once the digesta enters the small intestine, it is neutralized by pancreatic 
secretion. During the transit, dilution effect occurs continuously in the stomach 
and small intestine by the gastric juice and pancreatic secretion, respectively. 
Viscosity is an important parameter to determine the ability of a polysaccharide 
to reduce glucose absorption. HE-CI is highly viscous and effective in lowering 
glucose diffusion and a-amylase activity. However, in the viscosity measurement 
and in vitro tests, the acidification, reneutralization and dilution effects occurring 
in the gastrointestinal tract were not considered. It is expected that these 3 effects 
modulate the viscosity of the HE-CI. 
The digestive tube of mice consists of an esophagus connected to the stomach 
which is a large dorsoventrally flattened sac located in the left anterior quadrant 
of the abdominal cavity. The small intestine is a coiled tube about 18 inches long, 
extending from pylorus to cecum and divided into duodenum, jejunum and ileum 
while the components of the large intestine includes cecum, colon and rectum. 
Cecum is an elongated blind sac in the lower abdominal cavity connecting the 
ileum to colon. The mouse has no vermiform appendix. The colon is not coiled 
and consists of an ascending section from cecum to the level of pylorus, a short 
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transverse section, and a descending section extending to the border of the body 
cavity. The rectum is outside of the body cavity and is a short, thick passage from 
the colon to anus (Hummel, Richardson and Fekete, 1966). 
The digestive system of mice is basically identical to human and thus HE-CI fed 
to mice also receives acidification in the stomach, reneutralization in the small 
intestine and dilution in the whole gastrointestinal tract. The relationship of in 
vitro and in vivo hypoglycemic effects of guar gum and xanthan has been studied 
in human. Although the in vivo systems are different (human in the literature and 
mice in the present experiment), both subjects share a very similar digestive 
system, and the difference in in vitro and in vivo hypoglycemice effect in human 
might help to explain the present situation in mice. 
In a study by Edwards and colleagues (1987)，it correlated the viscosity of food 
gums measured in vitro was correlated to their hypoglycemic actions. The food 
gums being evaluated were guar gum, xanthan gum, locust-bean gum and a 1:1 
mixture of xanthan gum with locust-bean gum and xanthan gum with Meyprodyn, 
which was a cold-water-soluble grade locust-bean gum. Among these 5 samples, 
the 1:1 mixture of xanthan gum with locust-bean gum had the highest viscosity 
but it only was equally effective as guar gum when tested in human. In order to 
better mimic the viscosity change in the GI tract, the viscosity of the samples 
should be measured after they are acidified to pH 2, and then measured again 
after neutralization. Equivalent amount of saline added to the acids used in 
acidification and base used in reneutralization was added to the 5 sample 
solutions to investigate the dilution effect. The viscosity of guar gum, locust-bean 































































































































































































































































































































































































































acidification, neutralization and dilution with saline (table 3.12). The work by 
Cameron-Smith et al. (1994) also showed the change of the viscosity of guar 
gum, xanthan gum and methylcellulose after acidification, neutralization and 
dilution. Edwards et al. (1987) suggested that a better correlation between the 
viscosity of polysaccharides and glycemic response could be obtained when the 
food gums were acidified and neutralized to simulate gastrointestinal 
environment. 
Thus, when HE-CI was orally administered to normal BALB/c mice, 
acidification of HE-CI to about pH 2 by hydrochloric acid and neutralization by 
pancreatic secretion, and the corresponding dilution effect possibly decreased the 
viscosity of HE-CI and resulted in the loss of ability to reduce postprandial 
hyperglycemia. In addition, HE-CI might behave like non-Newtonian solution 
with apparent viscosity decreasing with the increase in shearing rate. The 
contraction of the small intestine increases after ingestion, and this gives a higher 
shearing force, which in turn may possibly reduce the viscosity of HE-CI 
solution. 
Female mice were used to test the ability of HE-polysaccharides to reduce 
postprandial hyperglycemia. One of the problems associated with the use of 
female mice in the test is the cyclic hormonal fluctuation. Changes in the 
hormonal content of female mice might adversely affect reliability of the test 
results. Thus, male mice were used to evaluate whether sex difference would 
have any contribution on the results, but no difference between the two groups 
was found. Such results are expected as the mechanism of polysaccharides to 
reduce glycemic response is related to thier viscosity, a mechanistic action to 
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delay glucose absorption. It should not initiate any hormonal secretion to affect 
blood glucose level. 
To understand more on the viscosity of HE-CI under the effect of acid, base and 
dilution, HE-CI should receive acid treatment, neutralization and dilution by 
saline with a volume equivalent to the amount of acid or base added. Then the 
viscosity of the acidified HE-CI, neutralized HE-CI, and saline-diluted HE-CI 
should be measured. The viscosity of HE-CI measured under these conditions 
should give a more reliable prediction on the effect on the glucose absorption in 
small intestine. 
Despite the negative results of HE-CI in OGTT, it is worthy to further investigate 
glucose tolerance of normal individuals after ingestion of a diet with added 
HE-CI rather than HE-CI with glucose mixture. Wursch and Pi-Sunyer (1997) 
pointed out that the way gums were consumned had a significant effect on 
glyceinic impact. To maximize the hypoglycemic effect, gums must be mixed 
with food or consumed together. Chemical denaturation of the polysaccharides 
should be avoided as it will affect rheological properties of the polysaccharides, 
and consequently, glycemic response. When gums were taken before meal, there 
was no effect on glycemic response (Fuessl et al., 1986; Wolever et al” 1991). 
Thus, the ineffectiveness of a mixture HE-CI and glucose in lowering glycemic 
response might not be changed when HE-CI is incorporated into food. 
Higham and Read (1992) found that the addition of guar gum to the diet of 
testing subjects would reduce the viscosity of the ileostomy effluent. The authors 
proposed that it is not always reliable to predict the function of the small intestine 
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when guar gum was added to the diet, either alone or with glucose. For HE-CI, 
the properties of this fungal polysaccharide may be somehow different when 
ingested in a diet rather than mixed with glucose. 
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3.4.2 Establishment of a Diabetic Murine Model 
In order to evaluate the antidiabetic potency of the HE-polysaccharides, it is 
necessary to establish a diabetic murine model to verify their hypoglycemic 
activity. The establishment of a standard protocol to induce diabetic status in 
mice became one of the milestones in the present research. 
Type I diabetes was selected as the target diabetic murine model over type II 
because NIDDM can only occur in genetically inbred mice such as db/db mouse, 
ob/ob mouse and KK mouse (Rodrigues et al, 1999). The supply of type II 
diabetic mice was limited in the Laboratory Animal Service Center (LASEC) in 
our university, and a constant supply of type II diabetic mice for an extensive 
animal testing was not possible. In addition, the blood glucose level of type II 
diabetic mice elevates slowly, and it is necessary to monitor the plasma glucose 
level for a few weeks to decide when diabetic condition has appeared. In contrast, 
type I diabetes can be induced within 3-5 days in BALB/c mice by the injection 
of streptozotocin (STZ). Therefore, the number of animal in the test can be 
optimized to obtain more reliable results. 
Streptozotocin (STZ) [2-deoxy-2-(3-methyl-3-nitrosourea) 1 -D-glucopyranose] 
was used to induce diabetes in BALB/c mice. Alloxan is another available agent 
to produce diabetes in laboratory animals. STZ is used instead of alloxan due to i) 
greater selectivity of P-cells for STZ (Junod et al.，1969), ii) lower lethal rate in 
the STZ-induced diabetic animals (Hoftiezer and Carpenter, 1973), iii) longer 
half-life of STZ in the body (Weissbrod and Jain, 1980). The chemical structure 
of STZ is constituted of a glucose moiety with a highly reactive nitrosourea side 
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chain which is believed to be responsible for its cytotoxic action. The glucose 
part of STZ targets at pancreatic P-cells, where it binds to the membrane surface 
receptors and induces structural damage. On cellular level, 3 reactions are 
responsible for the death of p-cells: i) process of methylation, ii) free radical 
generation and iii) nitric oxide production. 
The induction procedure was adapted from Kurup and Bhonde (2000). It 
described the injection of STZ, reconstituted in chilled sodium citrate buffer with 
a pH of 4.5, at a dosage of 200 mg/kg body weight to eight-week-old BALB/c 
mice could induce diabetic conditions with a fasting plasma glucose level over 
200 mg/ml. The same procedure was followed but the outcome was not 
satisfactory. Four problems appeared in this procedure: 
i) High mortality rate. After injection of STZ at 200 mg/kg, the mice started to 
die progressively. In the worst case, in a group of 30 mice, after STZ injection, 
15 mice were dead after one week. 
ii) Fluctuation of plasma glucose level. In order to decide on the diabetic status 
of the mice, it is necessary to measure the fasting plasma glucose level. However, 
the fasting plasma glucose level in animals was not stable. For instance, the 
fasting plasma glucose level 5 days after STZ injection showed that the mice 
were diabetic. However, after 2 more days, the level would suddenly drop below 
the critical line (i.e. 200 mg/dL plasma glucose concentration). These confusing 
data made it difficult to determine whether the mice were diabetic or not. 
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iii) Aggressive behavior of mice. Before the measurement of fasting plasma 
glucose level, the mice needed to fast overnight. Some severely weak mice were 
not able to survive the fasting period and died. Their carcasses were eaten by the 
other mice in the same cage. It further complicated the reliability of the fasting 
plasma glucose value. 
iv) At the beginning of adoption of the induction protocol, a large number of 
mice remained healthy after STZ injection. 
After continuous testing and seeking advice from other researches from overseas, 
the dosage was lowered from 200 to 180 mg/kg body weight to lower the 
mortality rate. STZ was unstable in solution and therefore it was prepared just 
before use and once it was reconstituted in chilled sodium citrate buffer, it was 
injected into the mice within 2 minutes. 
Concerning the date for the measurement of fasting plasma glucose level, after 
repetitive measurements on 5, 7 and 10 days after injection of STZ, it was found 
that the level at day 5 most accurately reflects the diabetic status of the mice. 
According to Leiter (1985), an injection of STZ at doses between 150-300 mg/kg 
body weight in a single bolus would develop insulin-dependent diabetic state 
within 72 h in most inbred strain of mice. For those mice that were confirmed 
diabetic, they also suffered from other diabetic symptoms such as severe weight 
loss and polyuria. In order to maximize the number of diabetic mice to be used in 
subsequent testing, the diabetic mice were subject to hypoglycemic test on day 7 
and 8 after STZ injection, after which they might die due to other complications 
of diabetes. 
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According to Leiter (1985), an alternative schedule to induce diabetes in mice 
was also available. Like and Rossini (1976) induced diabetes in outbred Charles 
River CD-I male mice by a multiple ‘low’ doses scheme (i.e. STZ injected i.p. at 
40 mg/kg body weight daily for 5 consecutive days). In contrast to the 
occurrence of abrupt hyperglycemia in CD-I male mice treated by single STZ 
injection, multi-STZ injection gave a more slowly-progressing hyperglycemia 
preceded by (3- cell necrosis. Leukocytic infiltration of the damaged islets 
(insulitis) was the salient feature of the islet in CD-I males treated with 
multi-injection scheme. 
3.4.3 Hypoglycemic Activity of HE-polysaccharides in Normal Mice 
HE-CS at dosages of 100, 200 and 300 mg/kg and HE-CI at 100 mg/kg were 
injected into the intraperitoneal cavity of normal BALB/c mice to evaluate their 
hypoglycemic potency. The results are shown in table 3.13. Three hours after 
injection, HE-CS at 100 and 200 mg/kg reduced the blood glucose level 
significantly to 79.53% and 81.22%, respectively. However, HE-CI and a higher 
dosage of HE-CS (300 mg/kg) did not show significant blood glucose reduction 
3 h after injection. The blood glucose level in the mice 6 h after injection was 
significantly lowered by HE-CI and all the dosages of HE-CS, but these 4 groups 
were not significantly different from one another. At 24 h, HE-CI still maintained 
its hypoglycemic action with the blood glucose level lowered to 40.54%. 
However, the number of mice in this group was reduced to 2. The hypoglycemic 
action of HE-CI was not only significantly different from the control group, but 
also from the other 3 HE-CS test groups. For the 3 HE-CS groups, the blood 










































































































































































































































































actions of HE-CS at 3 dosages were not significantly different from each other. 
HE-CS and HE-CI show consistent hypoglycemic activity on normal mice 3, 6 
and 24 h after injection. However, despite the increase in dosage of HE-CS, no 
dose-dependent relationship was observed. The hypoglycemic effects of 100, 200 
and 300 mg/kg HE-CS were not significantly different from each other, and the 
effect started to diminish 24 h after injection as the percentage of relative plasma 
glucose level started to rise. For the HE-CI-injection group, although three mice 
were found dead 24 h after injection, it did not necessarily mean that HE-CI 
posed harmful effect on BALB/c mice. In another hypoglycemic test of HE-CI 
with the same dosage (100 mg/kg), the whole group survived and their blood 
glucose 3, 6 and 24 h after injection were 85.25%, 50.16% and 48.26%, 
respectively, with 6- and 24-hour blood glucose level being significantly lower 
than the control. Thus, the death of the HE-CI-injected mice might be due to its 
high viscosity which adversely affect the health of mice. In hypoglycemic tests of 
both HE-CI and normal mice, in contrary to HE-CS, hypoglycemic effect 
remained 24 h after injection. 
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3.4.4 Hypoglycemic Activity of HE-polysaccharides in Diabetic Mice 
The antidiabetic potency of HE-DP from the small-scale extraction was 
evaluated. Injection of HE-DP at 100 mg/kg led to significant blood glucose 
reduction at 3 and 6 h. The blood glucose levels of the diabetic mice were 
reduced to 91.39% and 80.04% at 3 and 6 hours, respectively (table 3.14). For 
HE-CSD, the blood glucose level was also significantly decreased at 3 and 6 
hours (78.22% and 68.72%) after injection at a dosage of 100 mg/kg (table 3.15). 
Table 3.16 shows the antidiabetic test results of HE-CS at 100, 200 and 300 
mg/kg body weight. Among the 3 dosages, 100 mg/kg did not give significant 
blood glucose reduction after injection, while in the group injected with 200 
mg/kg, blood glucose level was significantly reduced to 81.04% at 3 h and 
57.56% at 24 h. Despite significant blood glucose reduction at 3 and 6 h after 
injection at a dosage of 300 mg/kg, the whole group was found dead 24 h after 
injection. 
The antidiabetic activity of HE-CI is shown in table 3.17. Antidiabetic function 
was evaluated at dosages of 50, 100 and 150 mg/kg. Blood glucose level of the 
diabetic mice dropped significantly 24 h after injection of HE-CI. At a dosage of 
150 mg/kg, blood glucose did not decrease significantly 3 and 6 hours after 































































































































































































































































































































































































































































































































































































































































































































































































































































































In the test with diabetic mice, the hypoglycemic action of HE-polysaccharides 
was not as stable as they were in normal mice. In the HE-DP and HE-CSD 
groups, significant glucose suppression was found 3 and 6 h after injection, with 
the lowest plasma glucose level at 6 h，and the blood glucose level rose 24 h after 
injection. In studying the hypoglycemic effect of HE-CS, the results did not 
clearly show a dose-dependent relationship. At 100 mg/kg, HE-CS did not 
exhibit significant inhibition on glucose rise while increasing the dosage to 200 
and 300 mg/kg did occasionally suppress the blood glucose. In the HE-CI group, 
fluctuation in plasma glucose values was even greater, as reflected from the 
standard deviations. Significant glucose reduction was observed at 24 h after 
injection of HE-CI at 50 and 100 mg/kg. 
The first hypoglycemic test of HE-polysaccharides was conducted on HE-DP to 
test the presence of antidiabetic function of polysaccharides extracted from H. 
erinaceus. The test had been repeated (results not shown) and the positive results 
led to more intensive study of the HE-polysaccharides. 
In comparing the hypoglycemic effect of HE-CS and HE-CSD (the deproteinized 
form of HE-CS) under the same dosage (i.e. 100 mg/kg), HE-CSD gave a 
promising glucose reduction 3 and 6 h after injection while HE-CS did not. One 
possible explanation for such difference was the injection of higher amount of 
active polysaccharides into the diabetic mice. As HE-CSD was deproteinized 
from HE-CS, thus when the doses of injection were the same, the amount of 
polysaccharides being injected into the mice were higher in HE-CSD. For 
instance, the acidic polysaccharide, TAP, isolated from the fruiting body of T. 
aurantia was effective in lowering the blood glucose level in the diabetic mice. 
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However, the TA-70E, it was the crude polysaccharide where the TAP was 
extracted from could not significantly lower the blood glucose in the diabetic 
mice (Kiho et al., 1995). This example reveals the importance of purification to 
obtain an active fraction from the crude extract. However, from the 
physico-chemical properties analysis of HE-CS and HE-CSD, the difference in 
their protein content is about 1.2%. Thus, whether such a difference will cause 
the variation in the hypoglycemic activity remains questionable. 
In fact, from table 3.16, the relative plasma glucose values of the HE-CS-treated 
groups were lower than the control groups, but the values were significantly only 
in some circumstances. When the plasma glucose values of individual mouse was 
studied with details, usually 1-2 unresponsive mice in the group would elevate 
the average relative plasma glucose level and the standard deviation. Thus, when 
analyzed by student's t-test, the high deviation resulted in insignificant results. 
When repeating the experiment, same results were obtained. The blood glucose 
level was lower than that of control after injection of HE-CS, but without any 
significance. To improve the situation, the number of mice being tested in each 
group should be increased in order to minimize the effect of the outliners (Kahn 
and Jandreski, 2003; Quimby, 1999). 
In the test of HE-CI, significant inhibition was found at later time periods after 
injection, probably due to the viscous nature of the polysaccharides. As HE-CI is 
highly viscous, the time for HE-CI to reach the active site to function would be 
longer than other aqueous solutions. Therefore, significant hypoglycemic action 
was found 24 h after injection. However, due to the viscous nature of HE-CI, the 
injection dosage should be carefully adjusted. In the group injected with 300 
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mg/kg HE-CI, the highly viscous nature of HE-CI may obstruct the normal 
circulatory system of the diabetic mice and resulted in the death of the whole 
group of mice 24 hours after injection. 
Dose-response relationship was not observed in HE-CS in both the normal and 
diabetic mice, which might be due to the colonic bacterial fermentation of 
HE-CS. The mechanism of undigestible carbohydrate to improve glucose 
tolerance had been suggested to be related to the production of short-chain fatty 
acids, acetic, propionic and butyric acids, by the fermentation of colonic bacteria 
(Cummings, 1983; Venter and Vorster, 1989; Wolever et al., 1989). Thus in this 
circumstance, the rate of fermentation of different dosages of HE-CS by the 
colonic bacteria to give hypoglycaemic short-chain fatty acids is an important 
factor to establish dose-response relationship. The rate of fermentation of various 
dosages of HE-CS in both the normal and diabetic mice might be remained 
constant and in consequences, no dose-response relationship was observed in the 
hypoglycaemic test. 
3.4.5 Change of Plasma Insulin Level in the Hypoglycemic Test 
The plasma insulin levels in the hypoglycemic tests of normal (3.7.1) and 
diabetic mice (3.7.2) were measured and the results are shown in table 3.18 and 
3.19, respectively. In normal mice, the insulin level of the control group peaked 
at 3 h (406.21%) while in the HE-CS and HE-CI-injection groups, the insulin 
peaked at 6 h with their corresponding relative insulin level being 302.98% and 
265.99%, respectively. The increase in insulin level in the control group was 























































































































































































































































































































































































































































































peaks (figure 3.16). 
In diabetic mice, the insulin level of the control group remains at a high level at 3 
and 24 h, (285.62% and 254.04%, respectively). In contrast, the insulin levels in 
the HE-CS group are lower at 3 and 24 h (72.25% and 71.94%, respectively) 
after injection. In the HE-CI group, insulin level was increased to 113.16% at 3 h 
and 163.01% at 24 h. 
One of the mechanisms to reduce plasma glucose level is to increase insulin level 
so as to promote glucose uptake by liver and muscle tissues. An active 
antidiabetic polysaccharide isolated from G lucidum, ganoderan B，could 
stimulate insulin secretion in normal and glucose-loaded mice (Hikino et al., 
1989). Therefore, reduction in plasma glucose level by HE-CI and HE-CS could 
be mediated through the same mechanism. However, the plasma insulin level of 
the HE-polysaccharides-treated normal mice was not significantly decreased 
when compared to the control. A similar trend was found in the diabetic mice, the 
insulin level of the HE-CS- and HE-CI-injection diabetic mice levels was lower 
than the control, but with no statistical significance. Thus, the hypothesis of 
increased insulin secretion to lower the blood glucose was not supported, and 
other mechanisms may contribute to of lowering the plasma glucose. 
In the mechanistic study of the hypoglycemic activity of ganoderan B, apart from 
stimulating insulin secretion, it also increased the activity of hepatic glucokinase， 
phosphofructokinase and glucose-6-phosphate dehydrogenase and decreased the 
activity of hepatic glucose-6-phosphatase (Hikino et al., 1989). Similar results 
were also reported in the hypoglycemic study of the antidiabetic study of the 
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acidic polysaccharide (TAP) extracted from T aurantia (Kiho et al., 2000b). 
Glucokinase and hexokinase catalyze the conversion of glucose into 
glucose-6-phosphate, which enters glycolysis for the generation of energy. 
Phosphofructokinase accelerates the conversion of fructose-6-phosphate to 
fructose-1,6-bisphosphate in glycolysis (figure 3.17); while glucose-6-phosphate 
dehydrogenase is the enzyme participating in the pentose phosphate pathway, 
responsible for the dehydrogenation of glucose-6-phosphate to 
6-phosphoglucono-5-lactone as shown in figure 3.18 (Lehinger et al., 1993). The 
activities of all these enzymes utilize glucose as the substrate to yield energy via 
ATP in glycolysis and NADPH in pentose phosphate pathway. Thus, increasing 
the activity of these enzymes can help remove circulating blood glucose and 
maintain a lower glucose level. Glucose-6-phosphatase is responsible for the 
breakdown of glycogen into glucose, and inhibition of this enzyme can decrease 
plasma glucose level. 
Therefore, improvement in glucose homeostasis in diabetic mice might be related 
to increasing the activity of enzymes for glucose metabolism and suppressing the 
conversion of glycogen into glucose, rather than elevation of insulin secretion. 
This needs to be verified by further work on enzyme activities. 
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Figure 3.17 The glycolysis pathway. Enzymes indicated in the jagged boxes 
are subject to various regulatory factors, (adapted from Bezkorovainy and 
Rafelson, 1996). 
137 
七 OH _ ^ 0 H a P 0 3 _ ^ 0 H 2 P � 3 
1 /一A T P ADP + P, A~O MADP NADPH A~O 
^ ^ I OH Hexokinase HO ] Glucose-6-phosphate ^ T 
Glucose Glucose- dehydrogenase 6-Phospho-
6-phosphate gluconoiactone 
, Qlucono- r 
actonasG�"令 
H H 
H-COH2PO3 H-COHjPOa HO-C-H NADPH NADP HO-C-H 
HO-C-H ^ ^ J HO-C-H 
0=C-H 6-Phosphog luconate 0=C-H 
H,C dehydrogenase H,C 
O-Ri^ulose- 6-Phospho-
5-phosphate gluconate 
Ribulose S - p h o s p h a t e \ R i b u i o s e 5-phosphate 
isomerase y / ^ Xw 3-epimerase 
H-C0H2P03 H-C0H?P03 




Ribose- D-Xylulose-5-phosphate 广 5-phosphate~^v^ 
Transketo lasey 
A^OH^POa ( T P P ) 人 H T 八 H-COH2PO3 
I ^ V H - C - O H - T ^ V + H 
Glucose- H-COHzPOa H - C - O H 
6-phosphate H - C - O H H O - C - H 
W H 人。 
\ HO 
Glucose \ D-Glyceraldehyde- n ^edohentuiose-
6 - p h o s p h a t e \ 3-phosphate 7 - p S s p h T t e 
i somerase \ ^ S . 广 
^ Transaldo laseY 
严 — � H人 Y � 
HO ‘ I Fructose H-COHjPO. » 6-phosphale H H-COH2PO3 t I工 O p : � H-foH V T r a二a s久 ^ GP二二二s 
乂 D-Glyceraldehyde-
3-phosphale 
Figure 3.18 The pentose-phosphate pathway for the generation of NADPH 
(adapted from Kohlmeier, 2003) 
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3.4.6 Comparison of Hypoglycemic Activity of HE-Polysaccharides in 
Normal and Diabetic mice 
3.4.6.1 Severity of Diabetic Conditions Induced 
The effect of HE-CS and HE-CI on the plasma glucose level in normal mice and 
diabetic mice was different. Obviously the hypoglycemic effect exerted on 
normal mice was more effective, stable and consistent; while the effect on 
diabetic mice showed a higher degree of fluctuation over time. One explanation 
accounting for such difference was the variation in the physiological responses to 
the HE-polysaccharides in the diabetic group. Although the mice were confirmed 
diabetic by the fasting plasma glucose value (diabetic when fasting plasma 
glucose value > 200 mg/dL), the severity of diabetes developed in individual 
mice was different. This could be reflected from the fasting plasma glucose 
values, ranged from 200 mg/dL to as high as 400 mg/dL. Some diabetic mice 
were clearly weaker than the others. Thus, it was possible that the effect of 
HE-CS and HE-CI in mice developed with later stage of diabetes (more serious 
conditions) was not as remarkable and potent as in the mice with early onset of 
diabetes (less severe conditions). By calculating the average plasma glucose 
values, large fluctuation in the results was found. Thus, in some antidiabetic 
animal experiments, only the diabetic mice with blood glucose level falling t the 
desired range are chosen for subsequent testing. Kiho and colleagues (2002) 
tested the anti-diabetic effect of TAP on genetically KK-A^ mice with the blood 
glucose level of 367-460 mg/dL. 
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3.4.6.2 Change in Insulin Secretion 
In the beginning, the difference of the hypoglycemic effect of 
HE-polysaccharides in normal and diabetic mice was hypothesized due to the 
insulin secretion. As mentioned before, hypoglycemic active ganoderan B from G 
lucidum (Hikino et al., 1989)，helped reduce the plasma glucose level by 
stimulating insulin secretion. As the pancreatic p-cells were damaged by the 
injection of streptozotocin, insulin secretion was impaired in the diabetic mice. 
The antidiabetic action of HE-polysaccharides would be less evident in the 
diabetic mice if HE-polysaccharides lowered plasma glucose level through the 
stimulation of insulin secretion. However, the measurement of insulin in the 
normal and diabetic mice did not support the above hypothesis as insulin level 
was not significantly elevated after the injection of HE-polysaccharides. 
3.4.6.3 Glucose Transporter 
GLUT2 is one of the glucose transporter located in hepatocytes, pancreatic 
P-cells, and absorptive epithelial cells of the intestinal mucosa and kidneys 
(Fukumoto et al., 1988; Thorens et al., 1988; Thorens et al., 1992). The most 
distinguishing feature of this glucose transporter from the other glucose 
transporters isoforms is that it is a low-affinity high-tumover system (Mueckler, 
1994). According to Gould and colleagues (1991), the exchange K,^  for GLUT2 
expressed in the Xenopus oocyte was 42 mM, compared to 18-21 mM of GLUTl. 
The high Km enables the liver to absorb postprandial glucose and the pancreatic 
p-cells to respond to a wide range of glucose change (Tuch et al., 2000). GLUT2 
has also drawn vast amount of attention as a participating molecules in the 
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pathogenesis of diabetes. In several diabetic models, such as autoimmune 
diabetic BB rats and Zucker diabetic fatty rat, the level of P-cells GLUT 2 was 
reduced (Johnson et al., 1990; Orci et al” 1990a; Orci et al., 1990b). An 
association was observed between reduced p-cells GLUT2 and decreased 
glucose-stimulated insulin secretion in streptozotocin-induced diabetic rats 
(Thorens et al., 1990). 
In streptozotocin-induced diabetic BALB/c mice, the level of p-cells GLUT2 
may decline after streptozotocin treatment. As proposed, the hypoglycemic 
mechanism of HE-CS and HE-CI might be mediated through the modulation of 
enzymes activities for glucose metabolism in the liver. Thus a reduction in P-cell 
GLUT2 might possibly decrease the amount of glucose transported into the liver 
for accelerated metabolism. However, transport of glucose in the liver was not 
affected in normal mice as the level of GLUT2 is not reduced. Thus, reduction of 
P-cells GLUT2 could contribute to variation of the hypoglycemic effects of 
HE-CS and HE-CI in normal and hypoglycemic mice. 
3.5 Other Factors that Affect in vivo Hypoglycemic Activity of the 
HE-polysaccharides 
3.5.1 Route of Administration: Oral Feeding and Intraperitoneal Injection 
There was no hypoglycemic action of HE-CS and HE-CI when it was orally fed 
to the BALB/c mice (section 3.4.1); however, it was found effective when it was 
injected into the intraperitoneal cavity of the mice. When tested by OGTT, the 
hypoglycemic effect was focused on the viscosity of the HE-polysaccharides to 
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reduce postprandial hyperglycemia. However when tested by intraperitoneal 
route of administration, mechanisms other than viscosity are being considered. In 
the antidiabetic study of fungal polysaccharides of G lucidum (Kimura et al., 
1988; Hikino et al., 1985; Hikino et al., 1989) and T aurantia (Kiho et al., 1995; 
Kiho et al., 2000a; Kiho et al., 2000b; Kiho et al., 2001; Kiho et al., 2002)， 
intraperitoneal route was employed as a mean of administration and 
hypoglycemic activity was due to changes of enzymatic activities for glucose 
metabolism rather than viscosity of ganoderan and TAP. After intraperitoneal 
injection, HE-polysaccharides were transported to the target site, for instance 
liver and muscle tissues, to exert its action. In OGTT, HE-polysaccharides could 
not be digested and passed on to the caecum where they might be fermented by 
bacteria, so the HE-polysaccharides could not enter the circulatory system and 
reach the active sites. Thus it was not surprising that hypoglycemic effect was 
observed only when HE-polysaccharides were intraperitoneally injected. 
3.5.2 Molecular Mechanisms of Hypoglycemic Activity 
The hypoglycemic actions of fungal polysaccharides are to increase insulin 
secretion and the metabolic breakdown of glucose, and to inhibit conversion of 
glycogen into glucose (Kimura et al., 1988; Hikino et al., 1985; Hikino et al” 
1989) and TAP from T aurantia (Kiho et al., 1995; Kiho et al., 2000a; Kiho et al., 
2000b; Kiho et al” 2001; Kiho et al” 2002). However, other pathways can lead to 
reduction of plasma glucose level without elevation of insulin. 
On the molecular level, the peroxisome proliferators-activated receptor isoform y 
(PPARy), a transcription factor, may represent a key mediator in the development 
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and metabolism of adipocytes, free fatty acids and glucose homeostasis (Stefan et 
al” 2001). PPARy was found in relatively high quantity in adipose tissue, colon, 
retina, and to a lesser extent in muscle and liver. PPARy regulated the protein 
required for the metabolism of glucose and lipids in the insulin-signaling 
pathway (Wagman and Nuss, 2001). The ligands of PPARy stimulated the 
replication of glucose transporter gene and leaded to the elevation of glucose 
transporter in muscle and liver (Wu et al., 1998; Young et al” 1995). The 
synthetic ligand of PPARy, thiazolidinedione, possesses antidiabetic function and 
stimulates glucose disposal by binding to PPARy in muscle (Spiegelman, 1998). 
It has also been shown that activation of PPARy induces the expression of c-Cbl 
associated protein (CAP) (Baumann et al., 2000; Ribon et al., 1998). CAP is a 
protein found in insulin sensitive tissues, and is involved in insulin-stimulated 
phosphorylation of c-Cbl that may play a role in glucose homeostasis. Thus, 
PPARy agonists reduce hyperglycemia without elevating insulin level by 
increasing cellular glucose uptake, suppressing glucose production, and 
increasing the sensitivity of insulin in resistant tissues (Wagman and Nuss, 2001). 
In fact, unsaturated free fatty acids are a kind of natural ligand of this receptor 
and in vitro infusion with mono- and polyunsaturated fatty acids activated PPARy 
(Forman et al.，1995). Thus, HE-polysaccharides could possibly act like free fatty 
acids to modulate glucose tolerance through the activation of PPARy. 
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3.5.3 Glucose Toxicity 
The hypoglycemic effect of HE-CS and HE-CI reduces the plasma glucose level 
in normal BALB/c mice. The reduction of plasma glucose level can prevent 
prolonged hyperglycemia which will lead to the development of diabetes or 
worsening the existing glucose intolerance in diabetes by exerting its effect on 
insulin resistance and insulin secretion of individuals. 
3.5.3.1 Insulin Resistance 
Insulin resistance is not an unique characteristics of NIDDM, but is also present 
in moderately and poorly-controlled IDDM patients. Insulin resistance was 
predominantly localized in the muscle tissue of IDDM patients (Yki-Jarvinen et 
al” 1990). Effect of hyperglycemia on the development of insulin resistance was 
shown in the study of glucose uptake of IDDM patients receiving continuous 
subcutaneous insulin infusion therapy after 24 h of hyperglycemia induced by 
intravenous glucose infusion, followed by 24 h of norglycemia (Yki-Jarvinen et 
al., 1987). The results showed that glucose uptake in the 24 h hyperglycemic 
period was lower than that in 24 h norglycemic period, showing that temporary 
hyperglycemia caused insulin resistance. In another study on the site of insulin 
resistance in IDDM patients, decrease in whole body insulin-stimulated 
utilization of glucose was localized in muscle tissue and nonoxidative glucose 
metabolism, mainly glycogen synthesis (Vuorinen-Markkola et al., 1992). 
Physiologically, glucose transport is the rate-limiting step for insulin-stimulated 
glucose utilization in muscle tissue of normal subjects (Katz et al” 1988) and 
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diabetic patients (Yki-Jarvinen et al., 1990). Since muscle tissue is also the major 
site of insulin resistance, glucose transport system is therefore the target 
down-regulated by hyperglycemia, but not other actions of insulin. In cultures of 
rat adipocytes, glucose only affected glucose transport but not protein synthesis 
(Marshall, 1989). In studying the effect of hyperglycemia on glucose transporters, 
GLUTl level was reduced after exposure to glucose (Klip and Paguet, 1990). 
GLUT4 concentration was reduced in muscles of streptozotocin-induced diabetic 
rats, in which glucose level was elevated 3 times with normal insulin 
concentration (Dimitrakoudis et al., 1991). These results show that glucose 
transport system was down-regulated by hyperglycemia. 
3.5.3.2 Impaired Insulin Secretion 
The relationship of hyperglycemia and impaired insulin secretion was 
demonstrated in animals models. In partially pancreatectomized dogs, high 
plasma glucose level was maintained for 2 weeks. Consequently, persistent 
hyperglycemia, loss of glucose-induced insulin secretion, ketonuria and weight 
loss as well as reduction in the size and number of islets were developed in the 
dogs (Imamura et al., 1988). In rats, 35% glucose infusion for 48 h caused a 
reduction in insulin secretion in response to glucose and 50% glucose infusion 
for 48 h resulted in a total loss of insulin response (Leahy, 1986). Reduction in 
GLUT2 expression in P-cells in insulin-deficient hyperglycemic animals, and 
p-cells desensitization to glucose, leading to impaired glucose-induced 
phosphoinostitide hydrolysis in the signaling pathway of insulin secretion are 
possible ways to reduce insulin secretion by hyperglycemia (Yki-Jarvinen, 1992). 
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Continuous hyperglycemia results in the impairment of insulin secretion and 
development of insulin resistance. As mentioned before, unlike IDDM, NIDDM 
is not an inherited disease. Impaired insulin secretion and high insulin resistance 
are two main factors contributing to the development of NIDDM. In order to 
prevent this disease, normal insulin secretion and sensitivity should be 
maintained. As HE-CS and HE-CI were only effective in reducing hyperglycemia 
in normal mice, they could lower the possibility of developing impaired insulin 
secretion and insulin resistance induced by hyperglycemia. 
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Chapter 4 Conclusions and Future Works 
The polysaccharides, HE-CS and HE-CI, extracted by hot water from the fruiting 
body of H. erinaceus, are protein-bound heteroglycans with a highly-branched 
structure. The constituent monosaccharides of HE-CS are glucose and galactose 
while glucose is the dominant sugar found in HE-CI. The present findings of the 
physico-chemical properties of HE-polysaccharides are consistent with those 
from previous studies of hot-water extracted polysaccharides from H. erinaceus. 
The HE-CI solution could inhibit glucose diffusion and decrease a-amylase 
activity in in vitro tests due to high viscosity. However, HE-CI did not 
significantly reduce in vivo glycemic response in oral glucose tolerance test. The 
conflicting results of HE-CI in in vitro and in vivo tests may be due to changes in 
viscosity in gastrointestinal tract in the murine model. Compared to HE-CI, the 
viscosity of HE-CS was much lower, showing negative results in the above tests. 
Both HE-CS and HE-CI could significantly reduce blood glucose level in normal 
mice after intraperitoneal injection; however, the hypoglycemic effect of these 
two polysaccharides in diabetic mice were significant only at higher doses and 
was subject to high fluctuation due to several reasons. The insulin level in normal 
and diabetic mice after injection of HE-CS and HE-CI was not elevated. 
Therefore, HE-polysaccharides ameliorated blood glucose level through 
mechanisms other than the stimulation of insulin secretion. 
Polysaccharides extracted by hot water from the fruiting body of H. erinaceus 
showed more promising hypoglycemic effect in normal mice. Thus, 
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HE-polysaccharides can be viewed as an agent to prevent development of 
diabetes and further worsening of existing diabetic conditions, since high blood 
glucose is a crucial factor in the development of diabetes and related 
complications. The suppression of blood glucose level by HE-polysaccharides 
under nondiabetic conditions can minimize the possibility of the onset of 
impaired insulin secretion and insulin resistance caused by hyperglycemia, 
leading to diabetes. 
To further investigate the hypoglycemic effect of HE-polysaccharides, the 
following experiments are suggested to provide a better understanding of the 
blood-glucose lowering mechanisms. 
1. The HE-polysaccharides should be fed to diabetic mice in the form of diet or 
aqueous solutions. The body weight, food intake, water intake, plasma insulin 
and urinary glucose should be monitored for a longer period of time such as 
one month. Horio and Ohtsuru (2001) conducted a similar experiment to 
study the hypoglycemic action of G. frondosa. It is possible that the beneficial 
action of HE-polysaccharides to diabetes only occur after a longer time of 
consumption. 
2. In this research, the hypoglycemic action of HE-polysaccharides was being 
evaluated on type I diabetic mice. It is also necessary to test the antidiabetic 
function in type II diabetic mice. It is expected that the antidiabetic effect of 
HE-polysaccharides would be more promising in type II diabetic mice. The 
blood glucose level of type II diabetic mice is slowly elevated after the onset 
of diabetes, but before the development of diabetes, blood glucose level is 
148 
normal. As HE-polysaccharides can help maintaining a low level of blood 
glucose in normal mice, injection of HE-polysaccharides to type II diabetic 
mice would better regulate the blood glucose within the normal range, 
delaying the onset of diabetes initiated by hyperglycemia. 
3. In the animal studies, apart from measuring plasma glucose and insulin 
level, enzyme activities in liver should also be measured to find out whether 
HE-polysaccharides can accelerate glucose metabolism and inhibit glucose 
breakdown to reduce hyperglycemia. 
Single injection of a high dose of STZ can induce damage in liver, kidney as 
well as cells of the immune systems, which will complicate the analysis of 
the metabolism of carbohydrate in different organs in diabetes. Therefore, 
when analysis of enzyme activity in liver is required, the induction protocol 
should be switched to a multiple low dose scheme to prevent complications. 
4. In vitro studies other than the measurement of GDRI and inhibition of 
pancreatic enzymes should be conducted. Protocols for the measurement of 
cellular glucose transport and glucose metabolism in vitro are available. In 
brief，the abdominal muscle from the recently-weaned postprandial male 
mice is incubated with ^H- and '"^C-labeled radioactive glucose solutions. 
After incubation with the presence or absence of the HE-polysaccharides, the 
tissues are hydrolyzed and the radioactivities of ^H and " c are counted for 
the glucose uptake (Gray and Flatt, 1999a). 
In oxidative glucose metabolism to carbon dioxide and incorporation of 
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glucose into glycogen, muscles are incubated with radioactive glucose. After 
incubation with the presence of HE-polysaccharides, carbon dioxide 
generated during the incubation period is captured on the filter paper 
saturated with sodium hydroxide and the muscle would be analyzed of 
glycogen. The radioactivity of carbon on the filter paper is counted and 
expressed as nmoles CCVmg muscle/hour (Gray and Flatt, 1999a). The 
amount of radioactive glucose being oxidized is indicated by the level of 
radioactive the carbon dioxide generated during the incubation. These two 
experiments can evaluate the ability of HE-polysaccharides to reduce blood 
glucose level by stimulating the glucose uptake and oxidative metabolism. 
For in vitro measurement of insulin secretion, BRIN-BDll cells, produced 
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